创立时间 01
2006 [CO002] 尽调报告
LigaChem Biosciences
这是一个战略可信的 ADC 平台，已有真实伙伴验证，2026 年资金弹药也更厚；但以已披露收入、当前验证深度和仍在发生的执行风险看，当前公开估值已经计入了相当多的未来成功。
LigaChem 的 ADC 平台可信，同阶段少见地拿到了强合作伙伴背书；但当前公开估值已偏高，除非看到更强人体证据、更清楚的 CMC 证据，或更便宜的入场价格，否则还难给出新的高置信买入结论。
封面要素
公司概况
LigaChem Biosciences 总部位于大田，是一家 KOSDAQ 上市的临床阶段生物技术公司，2006 年成立，2024 年由 LegoChem 更名而来。公司聚焦抗体偶联药物（ADC），核心是自有的 ConjuAll™ 偶联、连接子和载荷平台。历史上，商业模式主要围绕 ADC 资产和平台权利的对外授权，交易对象包括 Ono、SOTIO、Janssen、Iksuda、NextCure、CStone 等全球制药和生物技术公司；2026 年 National Growth Fund 牵头融资后，公司开始选择性把优先资产拉近自研。
- 成立时间
- 2006-01-01
- 创始人
- Yong-Zu Kim
- 创立地点
- Daejeon, South Korea
- 总部
- Daejeon, South Korea
- 产品
- LigaChem 的产品面是一套 ADC 平台加一组肿瘤资产组合，覆盖 HER2、CD19、B7-H4、CLDN18.2、LRRC15、L1CAM 等靶点，既有伙伴项目，也有自推进项目。
- 客户
- 全球制药和生物技术伙伴、肿瘤试验网络，以及由伙伴主导、偶尔由公司自推进的 ADC 开发项目最终触达的下游患者。
- 商业模式
- 以授权为主的 ADC 平台模式，资金来源包括首付款、里程碑、特许权使用费、商品销售和公开市场融资；2026 年战略开始转向核心资产的选择性后期自研。
- 阶段
- post-ipo
- 融资情况
- 公开证据支持公司在 2026 年 6–7 月完成 KRW 500B 的 CB/CPS 融资，历史授权收入也有实质规模，当前公开市场市值约 KRW 4.125T。公开来源没有清晰披露伙伴层面收入拆分、已兑现里程碑的质量，或完全勾稽后的当前现金头寸。
执行摘要
主要优势
- LigaChem 的 ADC 平台有真实深度，覆盖多类 payload、正在推进人体研究，并获得蓝筹合作伙伴验证。
- 2026 年 National Growth Fund 领投融资显著改善现金跑道和战略灵活性，强于较弱的临床期 biotech 同行。
- 过往授权和合作伙伴广度表明，复杂交易对手看重的是平台本身，不只是叙事。
- 活跃专利和公认的 ConjuAll™ 化学栈，为护城河提供至少一部分可见支撑。
主要风险
- 当前核心试验证据仍早期，本报告引用的在研人体研究没有保留下已发布结果。
- 公司正转向更烧钱的自研阶段，但公开 CMC 或商业化证据还不足以完全支撑这一转向。
- 公开经济性仍然不平滑且依赖合作伙伴，收入集中度、里程碑节奏和未来稀释风险透明度有限。
- 尽管证明深度低于战略并购先例，当前公开估值已较上市 ADC-biotech 可比公司隐含溢价。
- 客户、合作伙伴和区域权益复杂度高；即便底层科学可信，价值兑现也可能变慢或被摊薄。
未决问题
- 合作伙伴层面收入集中度、里程碑瀑布时间表和 royalty 转化历史。
- 任何自研路径的 CMC 质量指标、供应可靠性和上市准备度证据。
- ConjuAll 相关化学在关键司法辖区的完整自由实施权和专利格局分析。
- 当前公开目标价背后的详细分析师模型假设和情景概率。
- 把当前现金、单资产投入和现金跑道，与关键临床拐点重新对齐的更清楚口径。
目录
01公司概览
1.1 身份、上市状态与战略重点
严格从法律意义看，LigaChem Biosciences 不是一家未上市私人公司：官方历史、公司股票页面、Yahoo Finance 和 Stock Analysis 都显示，公司以 141080 为股票代码在 KOSDAQ 交易，IPO 时间为 2013 年。这个事实很关键，后续章节应把它视为一家具备创投式经济属性的上市生物技术公司，而不是典型风投支持的未上市初创。与此同时，公司的运营画像仍像一家平台型生物技术公司：公司自称处于临床阶段，总部位于大田，由药物化学驱动，聚焦 ADC 和免疫肿瘤。2024 年从 LegoChem 更名为 LigaChem 也影响来源辨识：较早的授权和媒体材料仍使用 LegoChem 品牌，而当前公司页面和 2026 年融资公告使用 LigaChem。[CO001, CO003, CO004, CO005, CO006, CO009]
| 指标 | 数值 / 状态 | 日期 | 置信度 | 缺口 / 提醒 |
|---|---|---|---|---|
| 总部 | 韩国大田 | 当前 | 高 | 除总部外另有首尔销售办公室 |
| 成立 | 2006 | 2006 | 高 | 创始人陈述与市场数据档案相互印证；未审阅可访问的公司注册文件 |
| 上市状态 | KOSDAQ 141080 | 当前 | 高 | 技术上已公开上市，因此本报告把它视为上市的创业型生物科技公司 |
| IPO 时间 | 2013 年 KOSDAQ IPO | 2013 | 中 | 基于官方历史，而非交易所招股书审阅 |
| 现名 | LigaChem Biosciences | 2024-03 | 高 | 较早资料仍使用 LegoChem |
| 核心方向 | ADC + 免疫肿瘤平台生物科技 | 当前 | 高 | 已审阅页面未披露直接的产品收入拆分 |
| 2026 年战略融资 | KRW 500bn | 2026-06-26 | 高 | 可访问来源未直接披露投后估值 |
| 融资前现金 | ~KRW 450bn | 2026-06 | 高 | 公司在股东问答和媒体摘要中的数字经过四舍五入 |
| 隐含融资后流动性 | ~KRW 900bn | 2026-06 | 中 | 来自新闻摘要推算，而非经审计资产负债表 |
| 商业牵引力代理指标 | 14 项全球授权交易 / 8 项全球试验 | 2026-06 | 中 | 来自 Korea Biomedical Review 摘要，不是公司主台账 |
快照表混合使用公司官方披露和韩国生物科技独立报道，因为公司没有发布完整合并 KPI 看板。
[CO003, CO004, CO005, CO006, CO009, CO013]1.2 领导层与治理
领导结构呈现创始人象征与职业化日常管理的分工。创始人 Yong-Zu Kim 仍以董事长和长期科学架构师身份出现；公开领导层页面和 Yahoo 资料则将 Sejin Park 列为 CEO 兼总裁。治理页面也显示，控制权已不再纯粹围绕创始人：与 Orion 相关的高管占据多个内部董事席位，说明 Pan Orion 2024 年成为最大股东后，持股地位已经转化为可见的董事会影响力。与许多亚洲生物技术同行相比，公司治理披露更强：董事会页面列出外部董事，披露出席率和会议频次。但它仍没有用英文完整说明委员会结构、保留事项权利，或创始人、管理层与 Orion 代表之间的实际影响力平衡。[CO007, CO008, CO010, CO011, CO012]
| 人物 | 职务 | 背景 / 代表群体 | 创始人-市场匹配或职能覆盖 | 关键人依赖 |
|---|---|---|---|---|
| Yong-Zu Kim | 董事长 / 创始人 | 创始人科学家代表，长期战略架构师 | 提供起源叙事、科学连续性和对外象征 | 高 |
| Sejin Park | CEO 兼总裁 | 领导层页面和 Yahoo 档案列名的运营负责人 | 负责上市公司执行和面向投资者的管理 | 高 |
| Young-Lag Cho | 首席开发官 | 领导层页面列名的资深开发高管 | 把管线衔接到临床开发 | 中 |
| Jeiwook Chae | 副总裁、R&D 负责人兼 ACB CEO | 公开列名的 R&D 负责人 | 串联核心 R&D 与波士顿地区子公司活动 | 中 |
| Chul-Woong Chung | ADC 研究院负责人 | 公开列名的 ADC 科学负责人 | 掌管 ADC 项目的核心技术路线 | 中 |
| Jinhwan Han | CTO | 公开列名的技术高管 | 支撑平台和工艺开发深度 | 中 |
| Orion 关联董事 | 董事会影响力阵营 | 治理页面列出 In Chul Heo、Suhwon Tam 和 Yong Su Kwon | 代表最大股东监督和战略控制输入 | 中 |
行项目列出公开披露、与尽调最相关的创始人、CEO、模态负责人和控制权人物，而不是穷尽所有公司页面提到的员工或顾问。
[CO007, CO008, CO011]1.3 资本形成与市场背景
2026 年 6 月 National Growth Fund 融资是本报告当前最关键的事实。公司公告和多家韩国新闻媒体都指向一笔 KRW 500B 交易，结构为 KRW 170B 可转债和 KRW 330B 可转换优先股，期限较长。公司强调，这笔钱专门投向 R&D 和后期临床开发，不用于 M&A；外部授权引擎仍保留，而不是被取代。这个点有分析意义：LigaChem 想增加选择性的后期自研能力，但不放弃已经贡献现金储备的授权机器。融资条款也试图在纸面上显得友好：无折价、延后转换权，并设置转让限制。即便如此，公开市场反应并不亢奋。NEWSTOP 报道公告当天股价下跌 8.28%，说明即便有国家背景资本背书，市场仍担心稀释、执行，或整个生物技术板块的疲劳。[CO013, CO014, CO015, CO016, CO017, CO018]
| 利益相关方 | 角色 / 进入点 | 控制权或经济重要性 | 尽调问题 |
|---|---|---|---|
| National Growth Fund / KDB 管理的战略基金 | 2026 年政策资本领投方 | 提供 KRW 250bn，并带来国家战略层面的背书 | 确认投票限制、保留权利和转换经济条款 |
| Pan Orion | 最大股东和 2026 年共同投资方 | 掌握董事会影响力，并在 2026 年融资中投入 KRW 125bn | 核对当前持股比例和任何控制权 |
| 未披露名称的第三方财务投资者 | 2026 年交易共同投资方 | 提供剩余 KRW 125bn，但可访问来源未披露身份和权利 | 获取投资者身份和补充协议条款 |
| KOSDAQ 普通股股东 | 公开市场流通股 | 承受稀释，并在股价中重估或惩罚融资策略 | 核对完全稀释股数和自由流通股 |
| Janssen / J&J | 最大可见授权交易对手方 | LCB84 交易潜在经济价值最高 $1.7bn，另有版税 | 评估概率调整后的下游现金回收 |
| Ono Pharmaceutical 和其他合作伙伴 | 平台和资产交易对手方 | 验证单一标志性交易之外的可重复授权模式 | 索取各合作伙伴首付款、里程碑和版税节奏 |
地图强调公开可见的控制权和经济边界，而不是完整股东名册或债务明细；后两者在已审阅材料中仍未披露。
[CO010, CO013, CO014, CO015, CO018, CO024]药物化学和 ADC 平台资产带来授权现金，反过来支撑 2026 年融资后的新增后期开发野心。
这张图展示因果逻辑，不是法律组织架构图，也不是精确现金流瀑布。
[CO006, CO021, CO022, CO023, CO024, CO025]公开披露的融资和市场指标显示，这是一家资金充足的上市生物科技公司，但后融资估值图景并未完全披露。
流动性、授权交易数量和试验数量是方向性指标，因为可访问的公开来源只是摘要披露，而不是给出单一经审计仪表盘。
[CO004, CO013, CO019, CO020, CO025, CO033]1.4 伙伴引擎与里程碑
LigaChem 当前的重要性，更多来自 ADC 伙伴机器的速度和规模，而不是产品收入。公司官方历史记录了与 Amgen、NextCure、Ono、J&J 的里程碑交易，独立媒体报道则给出了 J&J/Janssen LCB84 协议的具体经济条款。Korea Biomedical Review 补充了有用的规模指标：截至 2026 年 6 月，公司已有 14 笔全球授权交易和 8 项全球临床试验。如此密集的伙伴关系解释了为什么一家韩国上市生物技术公司能拿到异常大额的政策资本：国家基金资助的不是从零开始的科学项目，而是一个已经能把 ADC 资产放进全球管线的平台。2024–2026 年 LNCB74、LCB97/ONO-7429 和 LCB02A 的 IND 里程碑进一步说明，公司正把越来越多内部起源资产推过早期人体开发闸门。[CO023, CO024, CO025, CO026, CO027, CO028]
| 日期 | 事件 | 类型 | 金额 / 估值 / 状态 | 参与方 | 含义 |
|---|---|---|---|---|---|
| 2006 | 创始人成立 LigaChem Biosciences | 创立 | 公司成立 | Yong-Zu Kim | 后续 ADC 平台战略的起点 |
| 2013 | 以 141080 代码在 KOSDAQ IPO | 治理 | 上市公司状态 | LigaChem / KOSDAQ | 使公司在法律上成为公众公司，而非私营公司 |
| 2019 | ConjuALL 美国专利和 Takeda 时期平台授权活动 | 产品 | 平台验证里程碑 | LigaChem / Takeda | 显示 ADC 技术可规模化、可对外合作 |
| 2022 | Amgen 多靶点 ADC 合作和 NextCure B7-H4 ADC 协作 | 合作 | 全球合作提速 | LigaChem / Amgen / NextCure | 把药企认可度扩展到单一交易之外 |
| 2023-12 | J&J / Janssen 签署 LCB84 交易 | 融资 | 最高 $1.7bn 潜在对价 | LigaChem / Janssen | 形成标志性外部验证和现金潜力 |
| 2024-03 | 公司更名为 LigaChem；PAN Orion 成为最大股东 | 治理 | 品牌和控制权重置 | LigaChem / PAN Orion | 将公开身份和股权结构对齐到下一阶段 |
| 2024-12 | LNCB74 获得美国 1 期 IND | 监管 | 进入临床 | LigaChem / NextCure | 推动高优先级 ADC 走向人体验证 |
| 2026-04 | LCB97/ONO-7429 获得日本 1 期 IND 批准 | 监管 | 进入临床 | LigaChem / Ono | 显示近期合作 ADC 资产取得进展 |
| 2026-05 | LCB02A 获得美国 1/2 期 IND 批准 | 监管 | 进入临床 | LigaChem | 又将一个内部起源 ADC 推入临床 |
| 2026-06-26 | National Growth Fund 领投的 KRW 500bn 融资公布 | 融资 | KRW 500bn，无折价 | LigaChem / KDB 基金 / Pan Orion / 第三方投资者 | 为选择性后期自主开发能力提供资金 |
这条时间线结合公司历史、独立融资和交易报道，展示科学、授权、上市身份和资本形成如何相互强化。
[CO002, CO005, CO009, CO010, CO013, CO024]LigaChem 的公开演进，从 2006 年创立、2013 年 KOSDAQ IPO，到 2026 年围绕 ADC 授权引擎完成国家背景资本重组。
公开来源没有给出完整日历日期时，使用仅年份或月份级日期。
[CO002, CO005, CO009, CO010, CO013, CO024]1.5 剩余摩擦与如何使用这条基线
后续章节最稳妥的做法，是把公司官方历史、股票页面、2026 年 6 月融资公告，以及相互印证的韩国生物技术报道作为基准事实，同时明确保留若干未解缺口。公司显然已经上市，聚焦 ADC，融资能力也强于大多数临床阶段同行；但 2026 年融资的确切投后估值，在可获得公开材料中仍没有干净披露。未具名的第三家财务投资人、完整 cap table 权利，以及从现有现金到稀释调整后企业价值的精确桥接都还没有解决。公开运营指标同样不均衡：流动性可见，但员工数、收入结构、产品销售与授权收入的相对贡献，在本次可访问页面上没有清楚披露。因此，后续市场、财务和估值章节应依赖已记录的融资与管线进展，同时对缺乏支撑的封面指标保持保守。[CO001, CO004, CO013, CO019, CO020, CO036]
02市场分析
2.1 市场边界与实际购买对象
对 LigaChem 而言，相关市场比已获批 ADC 药物的下游销售更宽，但又窄于所有肿瘤治疗。公司材料显示，近期变现模式仍是资产授权和共同开发，因此第一层买方通常是希望获得 ADC 平台、靶点项目或载荷-连接子组合的大型制药或生物技术伙伴。这些买方所处的更大终端市场，则由医院、肿瘤中心和支付方最终决定某个已获批 ADC 能否触达患者。于是市场边界分成两层：上游 ADC 伙伴合作与开发需求，以及下游 ADC 治疗收入。两者都影响估值，因为健康的终端市场会支撑授权胃口；但全球 ADC 总销售额并不等于 LigaChem 能直接触达的收入池。这个框架也能避免尽调中的常见错误：把下游产品销售额等同于一家商业化前平台开发商能通过首付款、里程碑和特许权使用费捕获的更小收入池。[CM001, CM002, CM003, CM010, CM040]
| 细分 / 类别 | 纳入支出 | 排除支出 | 买方 / 支付方 | 关联度 |
|---|---|---|---|---|
| 已获批 ADC 疗法 | 已上市 ADC 品牌的净产品收入及配套给药需求 | 非偶联生物制剂和标准化疗收入 | 下游支付方和医疗服务提供方 | 最大的可见终端市场信号 |
| ADC 资产授权 | 平台或资产交易的首付款、里程碑和版税 | ADC 之外的广义生物科技合作 | 大型药企 / 生物科技合作伙伴 | 目前最贴近 LigaChem 现状 |
| ADC 临床开发 | 绑定 ADC 资产的临床试验和监管支出 | 与 ADC 无关的一般肿瘤研发 | 发起方和开发合作伙伴 | 显示管线深度和未来供给 |
| ADC 生产和 CDMO 产能 | 偶联、HPAPI、灌装封装和监管支持服务 | 通用生物制剂生产产能 | 开发方和外包伙伴 | 放大供给的关键瓶颈 |
本章把 ADC 视为双层市场：上游资产 / 平台变现，加上下游治疗销售和给药。
[CM001, CM002, CM003, CM010, CM040]LigaChem 首先卖给制药伙伴，但只有资产下游穿过报销和诊疗场景采用关口后，价值才会兑现。
流程描述的是经济采用逻辑，不是法律供应链。
[CM001, CM011, CM012, CM030, CM031, CM032]2.2 规模测算视角与需求集中地
公开 ADC 市场测算方向一致，但数字噪声很大。按不同方法，2026 年市场规模约在 USD 16.8 billion 到 USD 20.3 billion 之间；更长期预测则从 2033 年的 mid-USD 30 billions 到 2031 年超过 USD 70 billion 不等。与其假装某一个预测具有权威性，更稳的结论是：这个市场已经足够大，多数公开观点认为它保持两位数增长，并且仍集中在报销、生物标志物检测和肿瘤基础设施已经成熟的地区和适应症。乳腺癌和 HER2 相关疗法目前占主导；Asia-Pacific 是 LigaChem 这类韩国开发商最相关的增长地区，因为日本、中国和韩国的报销和本土 ADC 投资都在扩张。对 LigaChem 来说，这个区域增长故事比泛泛的全球 TAM 叙事更重要。[CM004, CM005, CM006, CM007, CM008, CM009]
| 发布方 | 年份 / 展望期 | 地域 | 数值 | CAGR / 增长 | 方法论信号 | 置信度 | 局限 |
|---|---|---|---|---|---|---|---|
| Grand View Research | 2023 to 2030 | 全球 | USD 11.29B 至 USD 24.01B | 9.2% CAGR (2024-2030) | 行业收入和细分份额 | 中 | 预测从 2023 年而非 2026 年开始 |
| Business Research Company | 2026 to 2030 | 全球 | USD 20.28B 至 USD 46.95B | 22.7% CAGR (2026-2030) | 按应用和终端用户测算出厂口径市场 | 中 | 商业供应商方法论不完全透明 |
| Research and Markets 数据 | 2025 to 2030 | 全球 | +USD 13.77B | 15.7% CAGR | 预测和供应商格局视角 | 中 | 增量增长口径不能与其他测算直接比较 |
| Mordor Intelligence | 2026 to 2031 | 全球 | USD 20.12B 至 USD 71.55B | 28.88% CAGR | 带有驱动因素和约束因素权重的专有模型 | 中 | 相比同业预测非常乐观 |
| Fairfield Market Research 数据 | 2026 to 2033 | 全球 | USD 16.80B 至 USD 35.99B | 11.5% CAGR | 产品和地区组合，并附可及性评论 | 中 | 长展望期和发布方假设可能平滑波动 |
| Fairfield Market Research 数据 | 2026 | 北美 | USD 6.72B | n/a | 全球市场的区域切片 | 中 | 区域份额不能直接代表 LigaChem 的 SAM |
正确结论是估值区间和集中度格局，而不是一个唯一的 TAM 数字。
[CM004, CM005, CM006, CM007, CM008, CM009]地理分层显示，相关 ADC 市场全球规模很大，且仍由可报销的发达市场锚定。
这是受约束的地理视角，不是 LigaChem 的字面 TAM/SAM/SOM 瀑布。
[CM006, CM034]公开 ADC 市场估算因方法不同差异很大，但都指向一个规模大、仍在增长的肿瘤类别。
低 / 中 / 高来自不同发布方，不是同一套内部一致模型。
[CM004, CM005, CM006, CM007, CM008, CM034]2.3 买方、支付方与采纳路径
下游 ADC 采纳路径仍高度依赖机构。医院主导当前给药经济学；市场报告也仍把医院和诊所描述为实际终端用户渠道，因为这些疗法需要输注基础设施、生物标志物检测、安全管理和报销协调。支付方控制同样强：NICE 对 Enhertu 的决定说明，即使临床表现出色，成本效果仍高于可接受门槛时，ADC 也可能被挡在外面；PADCEV 的支持材料则提醒医护，覆盖范围会随支付方和场景变化，治疗前必须核验。换句话说，科学有效性必要但不充分；真正的市场准入取决于指南位置、处方集接纳和报销流程。对 LigaChem 来说，任何伙伴不仅要把资产开发成功，还要在主要肿瘤市场穿过 HTA 机构、保险方和治疗场所经济学。[CM011, CM012, CM018, CM019, CM030, CM031]
| 细分 | 买方 | 用户 | 支付方 | 工作流 / 预算负责人 | 采用触发因素 |
|---|---|---|---|---|---|
| ADC 平台授权 | 全球药企和肿瘤生物科技公司 | R&D 和 BD 团队 | 企业 R&D 预算 | 交易团队和组合委员会 | 差异化资产或连接子-载荷平台 |
| 已上市实体瘤 ADC | 医院肿瘤科 | 肿瘤内科医生和输注团队 | 保险方 / 国家医保体系 | 药品目录和肿瘤预算负责人 | 有说服力的生存或缓解数据，加上生物标志物匹配 |
| 乳腺癌 ADC | 癌症中心和医院系统 | 乳腺肿瘤医生 | 公共和私人支付方 | 指南驱动的肿瘤预算 | HER2 或 TROP2 检测和适应症标签扩展 |
| 尿路上皮和血液肿瘤 ADC | 专科肿瘤中心 | 疾病领域专科医生 | 支付方和药品福利管理机构 | 治疗线报销决策 | 获批适应症与医生熟悉度 |
| 亚太准入扩张 | 当地医院网络与药企伙伴 | 肿瘤专科医生 | 国家报销方案 | 公共药品目录与采购机构 | 优先审评获批加价格谈判 |
各行把 LigaChem 当前的企业买方，与下游治疗渠道和支付方关口拆开呈现。
[CM011, CM012, CM030, CM031, CM032, CM035]每个 ADC 都必须穿过科学、监管、报销和交付关口，收入才能放量。
漏斗是有证据支撑的序位图，不是定量转化率模型。
[CM026, CM030, CM031, CM032]2.4 增长驱动、瓶颈与模式迁移
ADC 最强的多头逻辑已经不再只是「靶向化疗」。癌症发病率上升、临床试验快速扩张、标签扩展、生物标志物路径更丰富，以及双载荷、多特异性、免疫整合构型等平台创新浪潮，都在推高这个板块。大型既有巨头正在验证这种转向：Roche、Pfizer 等大型制药公司现在把 ADC 视为核心肿瘤平台，Pfizer 收购 Seagen 也显示，成熟偶联药物产品系列可以被赋予多高的战略价值。但瓶颈同样真实。制造仍昂贵且运营上高度专门化；开发背负剂量优化、免疫原性和药理学要求；报销仍可能因价格或证据不确定而失败。这组因素让 ADC 成为结构上有吸引力、但运营上低容错的市场——对 LigaChem 这类差异化平台拥有者有利，但前提是它们能持续比同行更好地解决载荷、连接子、安全性和伙伴执行问题。它也解释了为什么简单的市场增长标题会误导：即便品类高速增长，只有拿到制造产能、让监管满意并跨过报销门槛的开发商，才能把创新转成持久经济性。[CM017, CM020, CM021, CM022, CM023, CM024]
| 驱动 / 约束 | 方向 | 时间 | 影响 | 尽调问题 |
|---|---|---|---|---|
| 癌症发病率上升与精准肿瘤治疗转向 | 驱动 | 长期 | 扩大靶向治疗可触达患者池 | 跟踪适应症广度和生物标志物检测准备度 |
| 临床试验数量与适应症扩张 | 驱动 | 中期 | 增加可合作资产和获批适应症数量 | 监测在研试验和关键读出节奏 |
| 双载荷、双特异性和免疫整合型 ADC 创新 | 驱动 | 中期 | 可能拓宽实体瘤疗效并降低耐药 | 找出哪些平台方掌握下一波 IP |
| 大药企 M&A 与组合投入 | 驱动 | 短至中期 | 提高合作方兴趣，也验证品类重要性 | 梳理谁仍需要外部 ADC 资产 |
| 制造复杂度与 HPAPI 瓶颈 | 约束 | 当前 | 限制速度、推高成本，并利好规模化玩家 | 评估 CDMO 可得性和工艺稳健性 |
| 监管要求剂量优化和更多药理数据 | 约束 | 当前 | 相比更简单的生物药，增加时间和数据要求 | 审查剂量优化方案和安全性数据包 |
| 报销与 HTA 审查 | 约束 | 当前 | 即使获批也可能挡住放量 | 建模支付方敏感度和价格区间 |
| 替代疗法和更便宜的标准治疗 | 约束 | 当前 | 成本或安全性取舍不及预期时，限制渗透 | 与化疗、双特异性药物和 T 细胞接合器对比 |
这里有意把驱动因素和约束因素成对放在一起，因为 ADC 可以有战略吸引力，同时落地仍然很难。
[CM019, CM020, CM021, CM022, CM023, CM024]03竞争者
3.1 竞争格局：已获批 ADC 产品系列、平台同行与韩国相邻挑战者
LigaChem 的竞争格局必须按竞争发生的位置拆分。已获批产品层由 Daiichi Sankyo/AstraZeneca 的 ENHERTU、Pfizer/Seagen 的 ADCETRIS 组合、Gilead 的 TRODELVY 产品系列，以及 Astellas/Pfizer 的 PADCEV 项目主导。从当前窄口径看，这些公司不是 LigaChem 的直接销售竞争者，因为 LigaChem 还没有上市药物；但它们是最重要的基准竞争者，因为它们的产品系列定义了制药伙伴如今眼中经过验证的 ADC 表现。它们在标签广度、医生熟悉度、不良事件管理、编码支持和报销运营上都有证据。任何评估 LigaChem 管线或 ConjuALL 式化学体系的全球伙伴，都会把其潜力与这些可见参照标准比较。 第二层是独立或近期仍独立的 ADC 专家，例如 ADC Therapeutics、Sutro Biopharma，以及曾经的 Mersana。这些同行更像 LigaChem，因为它们销售平台、聚焦管线，或两者兼有，也必须说服伙伴或投资人相信，其化学体系或载荷架构足以拿到持久经济性。公开来源显示，这一组有真实技术雄心，但结果参差不齐。ADC Therapeutics 已进入商业化阶段，Sutro 仍在公开市场证明其下一代平台，Mersana 则通过现金收购失去独立性。第三层包括韩国和亚洲起源的挑战者，例如 Hanmi 的双特异性 ADC 工作，以及由中国带动的 ADC 交易流加速。区域压力很重要，因为它增加了同一批全球伙伴可选择的替代方案数量，而 LigaChem 正在争取的正是这些伙伴。[CP001, CP002, CP003, CP004, CP006, CP010]
| 竞品 | 类别 | 规模 / 融资信号 | 目标细分 | 核心差异化 | 相对 LigaChem 或龙头的主要短板 |
|---|---|---|---|---|---|
| LigaChem Biosciences | 授权驱动的 ADC 平台公司 | KOSDAQ 上市的临床阶段生物科技公司；多次达成全球合作 | ADC 平台合作和已合作管线 | 药物化学驱动的偶联平台和授权记录 | 尚无已上市 ADC，也未公开下游准入基础设施 |
| Daiichi Sankyo / AstraZeneca (ENHERTU) | 已获批 ADC 在位者 | 大型药企 / 全球肿瘤业务 | HER2 定义的多线实体瘤 | 最畅销 ADC；在引用竞品中可见适应症扩张最广 | 大药企标杆难以匹配；并非纯粹的平台对比同类 |
| Pfizer / Seagen / Takeda（ADCETRIS 主导组合） | 已获批 ADC 在位者 | 大药企规模，叠加收购来的 ADC 管线 | 血液肿瘤和更广的收购 ADC 组合 | ADCETRIS 8 个适应症；Seagen 交易后企业资源深厚 | 合作模式上与 LigaChem 可比性较弱；更偏商业化而非平台驱动 |
| Gilead (TRODELVY) | 已获批 ADC 商业化竞品 | 大型药企，具备正式肿瘤支持体系 | TROP2 驱动的乳腺癌业务 | 订购信息、福利核查和患者财务援助已可见 | 靶点覆盖窄于 ENHERTU；仍是商业化标杆，而非平台类比对象 |
| Astellas / Pfizer (PADCEV) | 已获批 ADC 商业化竞品 | 全球药企支持项目与支付方工具 | Nectin-4 尿路上皮癌业务 | 正式共付项目和支付方核验支持体现商业化准备度 | 按肿瘤类型看，聚焦范围窄于泛实体瘤平台叙事 |
| ADC Therapeutics | 专注 ADC 的上市公司专家 | 已进入商业化阶段，但仍像小市值专业公司 | 血液肿瘤；聚焦 anti-CD19，并扩展组合 | 一个 FDA 获批 ADC，且身份明确只做 ADC | 业务广度远窄于 ENHERTU 级别龙头 |
| Sutro Biopharma | 下一代平台挑战者 | 围绕平台叙事的上市公司 | 面向实体瘤的单载荷和双载荷 ADC | 双载荷定位瞄准耐药和下一代形态差异化 | 公开资料未披露可比的商业化证明或准入体系 |
| Day One / 收购 Mersana | 平台反面案例与资产挑战者 | 2026 年以现金加 CVR 被收购；已退市 | 靶向 B7-H4 的 Emi-Le 及相关 ADC 管线 | 显示差异化 ADC 资产在罕见肿瘤中的战略价值 | 失去独立性说明平台经济性尚未自我续航 |
| Hanmi Pharmaceutical | 韩国邻近挑战者 | 区域药企，AACR 2026 主动披露肿瘤管线 | 双特异性 ADC 和其他下一代肿瘤疗法 | BH4601 显示韩国本土竞争也在进入双特异性 ADC | 公开英文证据薄于全球龙头 |
规模 / 融资单元格只作方向性判断，因为公开资料混合了市场位置、上市公司状态和交易信号，无法给每一行提供统一现金数据。
[CP003, CP014, CP016, CP018, CP021, CP022]以序位方式展示平台差异化与临床 / 商业验证，覆盖与 LigaChem 相关的主要竞争者。
坐标轴是有证据支撑的 1 到 5 序位评分，不是收入或临床终点测量。X 轴 = 平台差异化；Y 轴 = 临床 / 商业验证。
[CP004, CP014, CP016, CP018, CP021, CP034]3.2 竞争者画像：基准最强在哪里，LigaChem 真正重叠在哪里
最强商业基准是 ENHERTU。官方患者和 HCP 页面显示，这个产品系列已覆盖多个 HER2 定义的乳腺癌场景、NSCLC、胃癌和 HER2 阳性实体瘤。BioMed Nexus 将其描述为最畅销 ADC，这个事实的意义不在于销售炫耀，而在于证明一套连接子-载荷系统可以成为具备可重复临床和商业扩张的平台。ADCETRIS 的疾病范围更窄，但依然重要，因为其官方材料强调 8 个适应症和超过十年的临床使用。TRODELVY 和 PADCEV 提供了另一层经验：二者都把标签与明确的订购、权益调查和共同支付支持页面配套，展示 ADC 获批后，规模化肿瘤商业化应是什么样子。 独立专家中，ADC Therapeutics 是最清晰、已经到达商业化的公开同行，尽管其重点比 ENHERTU 周围的广泛实体瘤雄心更窄，也更偏血液肿瘤。Sutro 依靠单载荷和双载荷工程的平台主张竞争，而不是依靠当前商业体量。Mersana 提供了最重要的反面案例：即便拥有差异化 B7-H4 ADC 和额外管线，它也通过收购和退市离场，而不是复利成长为持久的独立赢家。Hanmi 作为韩国相邻挑战者值得关注，因为其 AACR 2026 披露显示，它愿意推进双特异性 ADC 设计，这意味着 LigaChem 不能假设本土区域缺少技术路径创新。重叠因此是真实存在的，但今天主要集中在平台可信度、下一代化学体系和伙伴注意力上，而不是直接产品推广。[CP004, CP005, CP008, CP011, CP012, CP014]
| 购买标准 | LigaChem | ENHERTU / Daiichi-AZ | ADCETRIS / Pfizer-Seagen | ADC Therapeutics | Sutro | Hanmi |
|---|---|---|---|---|---|---|
| 当前已有获批上市 ADC | 否 | 是 — 多个 HER2 适应症 | 是 — 引用的患者页面列出 8 个淋巴瘤适应症 | 是 — 一个 FDA 获批 anti-CD19 ADC | 引用来源未显示公开上市 ADC | 引用来源未确认上市 ADC |
| 可见报销 / 支持基础设施 | 依赖合作伙伴；公司官网未公开显示 | HCP / 患者网站有部分信息；完整净价仍未公开 | HCP 网站和安全管理界面可见 | 引用公开来源未知 | 引用公开来源未知 | 引用公开来源未知 |
| 平台 / 化学差异化主张 | 是 — 下一代 ADC 平台，强调药物化学 | 是 — 临床验证的连接子-载荷家族 | 是 — 成熟的 MMAE/val-cit 范式和长期临床使用 | 是 — 聚焦 ADC 的组合和扩张策略 | 是 — 单载荷和双载荷无细胞平台 | 是 — AACR 2026 披露双特异性 ADC 模态 |
| 肿瘤场景覆盖广度 | 已合作且处临床阶段；广度尚未商业化 | 在引用样本中非常广 | 中等；引用材料聚焦淋巴瘤 | 引用材料中血液肿瘤聚焦更窄 | 引用材料中仍早期且由平台驱动 | 引用材料中仍早期，偏临床前 / 发现 |
| 独立商业耐久性证据 | 未验证 | 引用样本中最强 | 在血液肿瘤细分中强 | 部分 | 未验证 | 未验证 |
该矩阵比较的是公开证据，而不是内部能力。「未知」表示该单元格没有留存清晰公开支持。
[CP005, CP008, CP010, CP012, CP014, CP016]六项竞争标准的能力覆盖。未知单元格反映公开证据缺失，不代表确认不存在。
该图使用定性值，因为公开证据不够均一，无法对每个标准打数字分。
[CP013, CP014, CP016, CP021, CP030, CP034]3.3 能力、定价结构、分销力量与转换成本
能力比较是不对称的，因为已获批产品在位者和平台授权方解决的是不同工作。对 ENHERTU、ADCETRIS、TRODELVY 和 PADCEV 来说，公开证据覆盖标签、警示、包装、准入支持和治疗流程。对 LigaChem 来说，公开表面强调的是化学体系聚焦和伙伴导向。这意味着简单功能矩阵必须把若干格标为未知，而不能假装公司已经拥有尚未披露的下游能力。最干净的横向比较不是单疗程净价——这个数字并不稳定公开——而是合同结构。LigaChem 向伙伴收取首付款、里程碑和特许权使用费；在位者则通过已获批药瓶变现，再用报销和患者支持项目强化使用。 分销力量因此几乎完全掌握在大型制药在位者手里。它们控制肿瘤医生关系、覆盖资源、编码指导、现场报销团队和制造供应链。LigaChem 的模式让公司暂时不用搭建这整套能力，这是资本优势；但议价权也因此留给了已经拥有商业基础设施的伙伴。伙伴一旦选择某个 ADC 平台，转换成本是真实存在的，因为流程经验、转化数据集和制造工作流会变成资产专属。但签约前，多家并行考察很可能很高：公开市场和格局来源显示，供应商、中国起源资产以及大型制药公司获取 ADC 能力的路径都很多。LigaChem 的竞争问题因此是：差异化必须强到让伙伴不再把它当作众多化学供应商之一。[CP013, CP022, CP023, CP026, CP027, CP028]
| 竞品 | 公开价格 / 合同模式 | 包装或内含能力 | 折扣 / 支持信号 | 对 LigaChem 的启示 |
|---|---|---|---|---|
| LigaChem Biosciences | 授权合同模式：预付款、里程碑、特许权使用费；未披露已上市疗法价格 | 平台合作，而非面向患者的分销 | 公开特许权使用费安排未知；经济条款未充分披露 | 当前竞争点在上游合作经济性，而不是下游药瓶使用量 |
| ENHERTU | 留存页面未披露公开净价 | HCP 和患者适应症集合广；官网显示重复给药模式 | 覆盖支持存在，但留存来源未公开具体返利 / 折扣条款 | 标杆证明，准入障碍解决后，广泛适应症扩张能支撑一个业务 |
| ADCETRIS | 留存页面未披露公开净价 | 患者 / HCP 页面列出 8 个适应症和大量安全管理内容 | 支持与编码细节存在，但标准化价格透明度仍有限 | 显示成熟 ADC 商业化可以与沉重毒性管理负担并存 |
| TRODELVY | 未披露公开净价；HCP 准入页展示覆盖支持流程 | 180 mg 单剂量药瓶；福利核查和预授权协助 | 明确披露财务援助和无保险患者支持 | 商业化对手靠患者支持运营增加价值；LigaChem 目前把这部分外包给未来合作伙伴 |
| PADCEV | 未披露公开净价；支持材料强调覆盖核验 | 商业支持页面串起编码、覆盖和共付流程 | 披露商业共付援助最高 $25,000/年 | 即使标价仍不透明，获批竞品也常在准入服务上竞争 |
公开网页更适合看支持项目设计，而不是看实际净价。因此，本表聚焦合同模式和包装证据，不假装存在干净的价格可比性。
[CP002, CP011, CP012, CP013, CP030]3.4 护城河耐久性与反向竞争证据
LigaChem 护城河最强的论据是，重复授权活动说明外部公司认可其偶联和化学能力。但公开记录中，这条护城河仍只被部分验证，因为它还没有转化为一个已上市的自有产品系列，也没有转化为 ENHERTU 那种多适应症标签扩展。公开证据显示，这个板块已经挤满跨多个靶点的已获批产品，大型制药公司也已经习惯大规模收购或合作已降险资产。当 LigaChem 拿出有说服力的数据时，这会帮到公司；当买方能够让多个资产来源相互竞价时，这也会伤到公司。 本章里，反向证据尤其重要。Mersana 被收购说明，即使是差异化 ADC 平台，结局也可能是被卖掉，而不是独立复利。ADC Therapeutics 和 Sutro 相比主导已获批 ADC 的制药集团仍处于小市值位置，说明投资人仍怀疑独立 ADC 专家能否在缺少更广泛证明时捕获产品系列级经济性。与此同时，所有已获批龙头仍背负显著安全负担，BioMed Nexus 也强调制造产能仍困难且专门化。合在一起，这些信号意味着 LigaChem 的竞争耐久性不是靠泛泛宣称 ADC 有前景来赢，而是取决于其平台能否比拥挤的全球替代方案更快、更干净或更经济地持续产出可合作资产。[CP018, CP019, CP024, CP025, CP031, CP032]
| 护城河主张 | 威胁 | 严重性 | 为何现在重要 | 缓解措施 / 尽调问题 |
|---|---|---|---|---|
| 可复制的 ADC 化学能力能持续拿到授权交易 | 大药企可以并行获取多个外部 ADC 资产和平台 | 高 | 供应商拥挤，交易前单一平台议价力下降 | 按靶点或逐笔交易证明超额表现，而不是泛泛讲 ADC 前景 |
| 区域化学声誉构成壁垒 | 中国源头和韩国邻近项目正在增加可合作 ADC 资产供给 | 高 | 2026 年，亚洲范围内合作方替代选择正在变多 | 量化说明 LigaChem 的连接子-载荷或靶点选择数据为何更优 |
| 拥有平台能创造持久独立价值 | Mersana 被收购并退市，说明差异化平台仍可能失去独立性 | 高 | 负面同业结果直接压低估值假设 | 要求拿出后期读出和合作经济性的硬证据 |
| 商业化可以延后交给合作伙伴 | 如果 LigaChem 一直不搭建下游体系，合作伙伴会拿走分销和定价权 | 中高 | 准入支持项目现在已是可见竞争优势来源 | 说明哪些资产准备自研，哪些会长期对外授权 |
| ADC 科学本身就是护城河 | 已获批龙头已经拥有最强临床验证，而安全性和制造对所有人仍然很难 | 中高 | 在已有 23 个获批产品的市场里，仅靠模态新颖性不够 | 用明确外部标杆跟踪临床差异化、可制造性和安全窗口 |
每一行都把一项公开护城河主张与外部威胁信号对应。任何缓解措施都不能只靠营销话术完成；都需要数据或更多合同细节。
[CP019, CP025, CP027, CP032, CP033, CP034]用最能概括 LigaChem 竞争耐久性挑战的公开指标或方向性信号，做一张压缩视图。
数值采用精确引用数字；公开口径不可直接比较时，采用有证据支撑的方向性标签。
[CP018, CP019, CP023, CP030, CP034, CP038]04财务
4.1 收入模型：高毛利授权，还不是可重复产品经济性
LigaChem 已经报告了有意义的收入，但收入机制更接近平台变现，而不是传统生物医药商业化模型。官方 2025 年合并报表显示，收入为 KRW 141.553B，其中 KRW 121.161B 来自授权费收入，只有 KRW 20.392B 来自商品销售。这个结构很关键：公司已经证明能把科学合作转成现金，但最大科目取决于里程碑时点、伙伴决策和合同确认，而不是可重复的处方需求。Ono 一揽子交易展示了这种结构。公司披露潜在经济条款最高可达 $700 million 加特许权使用费；2026 年 7 月 LCB97 里程碑也显示，伙伴推进项目时，收入或现金可以突然跃升。 这个模型不应被绝对地视为低质量，因为授权收入可以带来优秀的增量利润率，也验证了平台的外部需求。但它应被视为低可预测性收入。公开披露没有干净列出按资产划分的伙伴集中度、里程碑时间表或特许权使用费阶梯。商品销售看起来真实且持续，但管理层和第三方资料都明确表明，它们在 ADC 授权引擎之后。投资人因此需要区分收入规模和收入可重复性：LigaChem 已经搭出变现引擎，但这个引擎仍由交易驱动。[CI001, CI002, CI003, CI004, CI024, CI025]
| 收入流 | 机制 | 单位 | 当前数值 / 状态 | 收入质量 | 尽调问题 |
|---|---|---|---|---|---|
| 授权费收入 | 来自合作项目的预付款、里程碑或其他授权收入 | KRW / 期间 | 2025 年 KRW 121.161 billion | 高毛利但波动大；取决于合作伙伴行为和里程碑时点 | 按资产披露合作伙伴集中度和里程碑时间表 |
| 商品销售 | 医疗器械和耗材收入 | KRW / 期间 | 2025 年 KRW 20.392 billion | 比里程碑更可重复，但战略解释不足 | 阐明商品线的产品组合、利润率和增长前景 |
| Ono 里程碑收款 | LCB97 交易下由临床事件触发的现金付款 | 按事件 | 2026 年 7 月里程碑 > 2025 年收入的 10%；确切金额保密 | 触发时是高质量现金，但时点不可预测 | 提供里程碑阶梯和事件定义 |
| 未来特许权使用费 | 合作商业化后按净销售额比例收取 | 合作伙伴净销售额的 % | 尚未公开披露或实现 | 可能具备耐久性，但时点和费率不透明 | 按重大交易披露特许权使用费区间和保留权利 |
| 自主商业化产品收入 | 若 LigaChem 内部推进重点资产，则来自直接销售 | 药品销售 / 药瓶收入 | 尚无 | 当前没有；若出现会实质改变商业模式 | 说明哪些资产计划自主商业化，哪些计划对外授权 |
对这家公司而言，收入质量不只取决于有没有收入，更取决于收入可重复性和合作伙伴分散度。
[CI001, CI002, CI003, CI004, CI024, CI025]| 价格 / 合同模式 | 标价与实际价格 | 折扣 / 未知项 | 来源 | 启示 |
|---|---|---|---|---|
| 合作交易下的授权费收入 | 在里程碑或合同条款允许确认时，体现为会计收入 | 具体交易时点和收入确认规则未公开披露 | 2025 年官方财务报表 | 营收可以跳升，但不代表需求可重复 |
| Ono LCB97 一揽子交易最高 $700 million，另有特许权使用费 | 最高包价，不是当前已实现现金 | 实际预付款、里程碑时点和特许权使用费率未完全公开 | Ono 官方交易新闻稿 | 有商业潜力，但可预测性仍有限 |
| 2026 年 7 月 LCB97 里程碑付款 | 与首例患者给药绑定的已实现现金事件 | 确切金额保密；公开估算采用高于上一年收入 10% 的下限 | Sedaily 里程碑文章 + 披露清单 | 特许权使用费到来前，里程碑可支撑流动性 |
| 商品销售 | 产品或耗材销售，而非授权 | 实际价格和毛利率未披露 | 官方财务报表 + Yahoo 资料页 | 仅有有限证据显示非授权收入可重复 |
| 2026 年 CB/CPS 融资 | 资本而非收入；BigGo 显示转股价为每股 KRW 149,300 | 披露无折价发行，但稀释路径取决于转股和未来股价 | 官方 Q&A + BigGo + WOWTALE | 改善流动性，同时嵌入未来转股敏感性 |
本章把变现合同和融资拆开。公司两者都有，但解决的是不同问题。
[CI018, CI020, CI024, CI025, CI026]ADC 平台活动如何转化为 LigaChem 报告收入，并最终带来现金生成。
节点把官方现状指标与公开合同结构合在一起；这是商业模式桥，不是会计台账。
[CI001, CI002, CI024, CI025, CI027]4.2 成本结构与单位经济性：毛利看起来强，经营模型还没有
公开成本结构说明，尽管 LigaChem 报告的收入在临床阶段生物技术公司中异常可观，公司仍不能按传统盈利能力判断。官方 2025 年报表显示，经营费用为 KRW 248.039B，其中 R&D 费用 KRW 216.908B，对应经营亏损 KRW 106.486B。换句话说，公司花在研发上的钱远高于总收入。Yahoo 的毛利润科目表面上好看，因为授权费几乎不带传统意义上的收入成本，但那只是经济性的第一层。更重要的问题是，公司还需要投入多少增量科研和临床开支，才能让未来里程碑继续出现。 因此，CAC 或回本周期这类经典 SaaS 单位指标不适合这门生意。这里的实际变现单位是交易、项目或里程碑，而不是重复订阅或交易群组。更有用的财务镜头是收入质量对比开发强度：已确认授权收入的毛利很高，但 R&D 强度极高，公司把资产推向更深开发阶段时，经营亏损也很大。商品销售或许能提供更稳定的收入，但其利润率和战略重要性披露不够清楚，无法锚定投资判断。结果是，经营模型在毛利层看起来有效率，在现金流层仍资本密集且脆弱。[CI005, CI006, CI007, CI008, CI013, CI028]
| 指标 | 数值 / 状态 | 可信度 | 重要性 | 尽调追问 |
|---|---|---|---|---|
| 许可费占 2025 年收入比例 | ~86% | 中 | 说明收入主要由交易条款驱动，而不是产品销售拉动 | 按合作伙伴拆分，并区分一次性确认与持续确认 |
| 研发支出占 2025 年收入比例 | ~153% | 中 | 说明公司尚未跑到自我造血 | 按资产拆分，并区分外包与内部支出 |
| 2025 年经营亏损 | KRW 106.486 billion | 高 | 确认现有模式即便账面收入很大，仍在亏损 | 提供月度现金消耗，以及亏损滚入 2026 年的桥表 |
| 2025 年经营现金流 | -KRW 124.533 billion（亏损） | 高 | 新融资前，最接近公开烧钱速度的指标 | 提供融资后 2026 年季度经营现金流 |
| 商品销售毛利率 | Unknown | 低 | 如果规模可观，可能是最可重复的收入线 | 披露商品线毛利率及战略角色 |
最有决策价值的指标是烧钱速度、合作伙伴依赖和单项目支出。传统 SaaS 指标不适合这里。
[CI003, CI005, CI006, CI007, CI009, CI028]从收入走到烧钱的公开财务桥。
除明确标为定性外，所有数值均为公开 2025 年数据。
[CI001, CI005, CI006, CI008, CI009]4.3 资本充足性：按 2025 年烧钱速度跑道不到 12 个月，随后 2026 年融资重塑局面
2026 年融资前，公开数字指向一家明显依赖外部资本的公司。官方和 Yahoo 现金流页面都显示，2025 年经营现金流出约 KRW 124.533B，年末现金约 KRW 98.650B。按这个简单口径，LigaChem 的跑道不到一年。2026 年资本重组大幅改变了图景。官方 Q&A 和多篇外部报道描述了一笔 KRW 500B 融资，拆分为 KRW 170B 可转债和 KRW 330B 可转换优先股，明确用于资助 R&D 和后期开发，而不是 M&A。公开报道还描述了转换限制、无折价发行，以及国家背景资本和 Pan Orion 的大额参与。 即便如此，资本充足性并不会因融资标题金额足够大就完全解决。公开来源对当前现金分歧很大，从约 KRW 60.7B 到 KRW 418B，甚至约 KRW 450B 不等，取决于来源和定义。差异很可能来自不同截点，或是否计入更广义流动资源，但这让单靠公开材料精确计算跑道变得不可能。此外，向更多自研转移意味着 2025 年烧钱速度很可能是下限，而不是上限。这轮融资显然买来了时间；如果多个资产同时在内部推进，它并没有消除未来融资风险。[CI009, CI010, CI011, CI014, CI017, CI018]
| 项目 | 公开值 / 区间 | 可信度 | 重要性 | 尽调追问 |
|---|---|---|---|---|
| 2025 年末现金及等价物 | KRW 98.650 billion | 高 | 2026 年融资前的流动性基线 | 核验 2025 年末经审计现金，并确认受限现金处理 |
| 2025 年经营性现金消耗 | -KRW 124.533 billion（亏损） | 高 | 说明独立运营资金续航期不足一年 | 确认融资后 2026 年 Q1/Q2 烧钱速度 |
| 2026 年融资规模 | KRW 500 billion | 高 | 改变流动性格局的融资事件 | 按批次核对到账时间与资金用途 |
| 2026 年融资结构 | KRW 170 billion CB 加 KRW 330 billion CPS | 高 | 决定稀释和到期结构 | 提供完整转股与锁定期安排 |
| 2026 年当前现金 / 流动资源 | 公开口径冲突：~KRW 60.7b、KRW 418b 或 ~KRW 450b | 中 | 卡住精确资金续航期测算 | 发布带口径定义的资金桥表 |
| 下一轮融资触发点 | 可能取决于自主开发节奏和后期临床开支，而不是眼前偿债能力 | 中 | 内部项目提速后，资金需求可能更早回头 | 披露截至 2028 年逐资产资本计划 |
2026 年后资本充足性明显改善，但精确资金续航期仍取决于管理层如何定义可用资金，以及核心资产自主推进有多激进。
[CI009, CI010, CI011, CI017, CI018, CI019]公开资料能支撑的关键财务输入边界和现金续航解读。
低 / 基准 / 高区间结合直接披露值；公开来源冲突处，用明确标注的解读边界处理。
[CI010, CI011, CI017, CI033, CI035, CI036]公开资本来源和计划用途如何映射到 LigaChem 的战略转向。
这张图展示融资逻辑，而非审计后的现金时点；它结合官方表述和外部对条款结构的报道。
[CI017, CI020, CI022, CI023, CI032, CI036]4.4 财务结论与剩余承销阻断点
公开结论是混合但可理解的。LigaChem 已经拥有真实的外部变现引擎：它能签授权交易，赚取里程碑触发的现金，并报告相对许多早期同行都很大的授权费收入。这是实质正面，因为它把公司与纯粹收入前平台故事区分开来。与此同时，模型还没有自我维持。经营亏损很大，经营现金流为负；选择性后期自研的战略动作，也提高了未来资本需求上升而不是下降的概率。Yahoo 上显示的市值和分析师目标同样说明，投资人定价的是管线可选性，不是近期现金生成。 因此，承销阻断点是具体的，不是泛泛的。投资人仍缺少伙伴层面收入集中度、单项目 R&D 预算、已实现特许权使用费阶梯、干净的当前现金勾稽，以及 2026 年资本会被每个自研资产消耗多少的精确视图。这些缺口比再说一句「ADC 是有前景的领域」更重要。有了它们，投资人才能认真建模跑道、稀释风险和盈利质量。没有它们，最稳妥的公开结论是：2026 年让 LigaChem 从资金承压变成资金延展，但没有让它从不确定变成可预测。[CI030, CI031, CI032, CI033, CI034, CI037]
| 缺失的非公开指标 | 对分析的影响 | 具体尽调路径 |
|---|---|---|
| 当前现金对账 | 阻碍清晰测算资金续航期 | 获取现金、等价物、短期金融资产和交割后到账资金的资金桥表 |
| 分合作伙伴收入集中度 | 无法判断收入质量 | 要求按主要交易对手拆分收入，并提供里程碑时间表 |
| 分项目研发预算 | 无法按资产预测烧钱 | 按管线资产索取项目预算、CRO 承诺和制造开支 |
| 版税与里程碑阶梯 | 无法估值未来授权经济性 | 审阅交易摘要和董事会批准的合同附件 |
| 商品销售分部经济性 | 无法评估唯一可见的非授权经常性收入线 | 索取分部毛利率和管理层说明 |
这些不是装饰性缺口。它们决定公司只是被新资本延长了寿命，还是已经获得足够资金跨过有意义的价值拐点。
[CI029, CI031, CI033, CI034, CI039]05产品与技术
5.1 产品到底是什么：平台 + 管线型 ADC 公司
LigaChem 的产品最好理解为一套技术栈加一个资产组合，而不是单一商业化药物。官方公司页面把业务定义在下一代 ADC 和药物化学上；管线页面则展示一组广泛的靶点-载荷组合，而不是一个旗舰模块。从客户工作流看，第一位客户通常是希望获得已对准靶点的候选物，或其背后偶联引擎的制药或生物技术伙伴。第二层下游客户是临床网络，它们必须把生物标志物阳性入组、给药排程和最终商业化落到运营上。这解释了为什么公司可以同时报告平台合作、单产品授权和内部推进资产。 产品地图已经相当宽。公开材料显示 HER2-MMAF、CD19-pPBD、B7H4-MMAE、CLDN18.2-Topo1i、LRRC15-MMAE，以及额外的双特异性或实体瘤项目，说明公司正通过多个生物靶点和多个载荷类别表达其平台。这种宽度很重要，因为它暗示公司销售的是可重复的化学与开发能力。但产品定义仍处于商业化前：公司还在证明这些资产能否从架构和早期临床设计，毕业为持久、已上市的肿瘤产品。[CE001, CE002, CE003, CE004, CE014, CE037]
| 资产 / 模块 | 主要用户 | 状态 / 成熟度 | 差异化 | 尽调缺口 |
|---|---|---|---|---|
| LCB02A (CLDN18.2-Topo1i) | 肿瘤临床试验中心 / 未来合作伙伴或内部团队 | 1/2 期招募中 | CLDN18.2 靶点加 Topo1 载荷；LigaChem 自主推进 | 尚未发布疗效结果 |
| LNCB74 (B7-H4 ADC) | 肿瘤临床试验中心 / NextCure 合作场景 | 1 期招募中 | B7-H4 靶点；定位为降低毒性 | 无公开结果；合作方证据仍早期 |
| IKS014 / LCB14 (HER2-MMAF) | Iksuda 全球开发网络 | 1 期招募中 | HER2 靶向，采用 MMAF，并具备位点特异性连接子表征 | 比较优势主张来自公司自身 |
| IKS03 / LCB73 (CD19-pPBD) | Iksuda 血液肿瘤试验网络 | 1 期招募中 | CD19 靶点搭配 PBD 载荷 | 尚未发布人体疗效数据 |
| SOT106 (LRRC15-MMAE) | SOTIO pre-IND 开发团队 | pre-IND 阶段，计划 2026 年下半年提交 IND | ConjuAll 衍生的 LRRC15 项目，带有临床前优效主张 | 人体试验准备度和 CMC 证据未公开 |
| LCB36 (CD20xCD22-pPBD) | 未来内部 / 合作伙伴血液肿瘤流程 | 按 2026 年路线图摘要，计划提交 IND | 双特异性血液癌方向拓宽平台模态 | 仅保留路线图层级公开证据 |
| LCB58A (CEACAM5) | 未来内部 / 合作伙伴实体瘤流程 | 按路线图摘要，计划明年启动全球试验 | 将平台延伸到另一类实体瘤靶点 | 仅保留路线图层级公开证据 |
资产成熟度最强的证据来自试验注册，最弱的是已发布人体读数。
[CE004, CE005, CE007, CE009, CE012, CE015]LigaChem 交付的产品是一套分层 ADC 技术栈，不是单一功能或单一药物。
[CE002, CE010, CE013, CE014, CE021]5.2 架构与运营工作流
对一家生物技术公司来说，LigaChem 的公开架构异常清晰，因为公司材料和试验记录暴露了主要设计组件。官方材料称，ConjuAll 技术栈的差异化来自位点特异性偶联、连接子稳定性、毒素释放和药代动力学特征。临床试验 API 随后显示，这套思路如何落到不同资产上：LCB02A 将 CLDN18.2 抗体与 Topo1 抑制剂载荷连接；IKS014 / LCB14 是靶向 HER2 的 MMAF ADC；IKS03 / LCB73 使用 CD19 抗体和 PBD 前药；LNCB74 则是靶向 B7-H4 的 ADC，采用 21 天静脉给药周期。这是真实产品架构，不是泛泛营销口号。 运营工作流很长，也分多阶段。团队先选择靶点和抗体，调校偶联和载荷设计，生成临床前证据；随后以生物标志物设门槛的临床试验经过剂量递增、剂量扩展，最终进入伙伴或自研决策。这个工作流是全球的，不是本地的：引用研究在美国、澳大利亚、新加坡、加拿大、欧洲和韩国招募。与此同时，模型仍依赖伙伴。SOT106 被明确描述为由伙伴主导开发、制造和商业化；Iksuda 投资则说明，LigaChem 有时通过股权和治理深化控制，而不是把每个职能都内部化。[CE002, CE006, CE010, CE011, CE013, CE014]
| 用户任务 | 当前流程 | LigaChem 方案 | 可衡量收益 | 限制 |
|---|---|---|---|---|
| 药企合作伙伴想要针对选定靶点的 ADC 候选物 | 选择抗体 / 靶点，谈判获取权利，开发或引进候选物 | 提供平台衍生候选物或平台授权 | 更快拿到多载荷 ADC 架构 | 合作伙伴经济性和里程碑时间仍不透明 |
| 试验中心需要生物标志物阳性的难治患者 | 筛查靶点表达，确认器官功能，按周期给药 | 提供方案定义的 ADC，并设定靶点特异入组标准 | 支持靶向入组，而不是非选择性化疗 | 流程仍慢，且高度依赖试验中心 |
| 合作伙伴想在全球推进实体瘤候选物 | 使用 ConjuAll 衍生资产，由合作伙伴主导 IND / 1 期路径 | 案例包括 SOT106、IKS014、LNCB74 | 多个资产已看到全球试验中心部署 | 商业化往往让 LigaChem 依赖合作伙伴执行 |
| LigaChem 想提高内部选择权价值 | 用新增资本保留优先资产，或后续自主推进 | 2026 年路线图报道重点提到 LCB02A、LCB36、LCB58A | 创造早期对外授权之外的选择权 | 抬高执行难度和烧钱复杂度 |
同一个平台可服务不同工作流：纯授权、联合开发，或直接自主推进。
[CE003, CE016, CE017, CE020, CE021, CE032]| 层级 / 组件 | 角色 | 依赖 | 风险 |
|---|---|---|---|
| 靶向抗体 | 决定肿瘤识别和内吞入口 | 内部发现或外部抗体伙伴 | 靶点异质性或内吞不足会削弱疗效 |
| ConjuAll 偶联 / 连接子层 | 连接载荷，并管理稳定性与释放 | 化学工艺 know-how 与 IP 持久性 | 公开专利深度和 CMC 可重复性披露不足 |
| 载荷层（MMAF、MMAE、pPBD、Topo1i） | 提供细胞毒机制 | 载荷特异安全窗和肿瘤生物学 | 类别毒性可能迫使入组标准或剂量上限收窄 |
| 临床运营层 | 剂量递增、生物标志物筛选、疗效评估、全球试验中心 | 研究者、监管机构、合作伙伴运营 | 主要试验尚未发布结果 |
| 合作伙伴 / 商业化层 | 为多个资产提供资金、制造或商业化 | 合作伙伴投入和试验执行 | LigaChem 可能无法直接控制下游成败 |
公开架构在分子设计上证据最强，在 CMC 和制造落地披露上最弱。
[CE002, CE010, CE013, CE014, CE021, CE029]一个平台概念如何变成面向患者的临床资产。
[CE003, CE021, CE022, CE037]产品技术栈同时依赖多个外部和内部关口。
[CE016, CE020, CE029, CE030, CE038]5.3 成熟度、路线图与依赖结构
成熟度图景混合，但在改善。LCB02A 已经进入首次人体 1/2 期设计，计划入组 191 人，时间线预计持续多年。LNCB74 正在 1 期招募。IKS014 和 IKS03 都在 Iksuda 旗下推进全球 1 期项目。SOT106 仍处于 IND 前，但公开目标是 2026 年下半年提交 IND。BigGo 和其他 2026 年报道又加了一层：LCB36 和 LCB58A 被描述为下一批将加速的项目，因为 LigaChem 正在超越纯外部授权。这让公司在临床阶段 ADC 平台中拥有少见宽度，但也提高了执行依赖，因为许多项目现在争夺资本、管理层注意力和制造规划。 平台的关键依赖很清楚。生物标志物检测和患者筛选逻辑是必需的，因为试验围绕靶点阳性人群设计。伙伴很重要，因为大量下游开发和商业化仍在 LigaChem 之外。监管方和试验中心很重要，因为领先资产都还没有发布成熟结果；它们仍是设计阶段或早期招募故事。制造同样重要，即使公开细节有限，因为载荷-连接子质量和 CMC 可重复性是这个类别的根基。因此，路线图令人兴奋，但还没有降险。[CE005, CE007, CE009, CE012, CE015, CE016]
| 日期 / 阶段 | 里程碑 | 状态 | 含义 | 来源 |
|---|---|---|---|---|
| 2025-01 实际 | LNCB74 1 期启动 | 已完成 / 持续招募 | B7-H4 项目已进入人体测试 | ClinicalTrials API + NextCure |
| 2026-03 发布 / 2026-08 估计 | LCB02A 1/2 期全球研究启动 | 招募中 / 启动年份 | CLDN18.2 自主推进项目从概念进入临床执行 | ClinicalTrials API |
| 2026 H2 计划 | SOT106 全球 IND 申报 | 计划中 | 合作伙伴衍生 LRRC15 项目检验平台可迁移性 | LigaChem 新闻稿 |
| 2026-07 确认给药里程碑 | Ono 体系下 LCB97 首例患者给药 | 里程碑已完成 | 说明平台仍在推动下游项目进展 | Sedaily 里程碑 |
| 2026 年路线图摘要 | LCB36 明年 IND 计划 | 计划中 | 释放双特异性 / 血液肿瘤扩张信号 | BigGo |
| 2026 年路线图摘要 | LCB58A 明年启动全球临床 | 计划中 | 释放更广实体瘤扩张信号 | BigGo |
路线图证据最强的是已绑定注册试验或有日期的合作伙伴里程碑；最弱的是只出现在路线图报道里的下一波管线项目。
[CE005, CE007, CE009, CE015, CE022, CE032]公开证据显示架构很宽，但不同资产成熟度不均。
[CE005, CE007, CE009, CE012, CE015, CE032]5.4 信任、安全与质量控制
公开来源中最强的信任信号不是认证，而是方案纪律。ClinicalTrials 材料显示，研究受 FDA 监管，设有明确的剂量递增和剂量扩展结构，使用 RECIST 或 Lugano 等客观缓解指标，要求 ECOG 体能状态、器官功能阈值，并设置产品特异性排除标准。LNCB74 排除既往 MMAE-ADC 暴露、ILD/pneumonitis 病史、神经病变和角膜疾病。LCB02A 排除既往 Topo1 ADC 暴露。IKS014 排除 ILD/pneumonitis 和临床显著眼部异常。这些都是具体迹象，说明公司及其伙伴理解类别特异性安全负担，并在设计中绕开这些风险。 但信任缺口仍然重要。引用资产没有公开的制造认证、批放行指标、供应可靠性统计，或已发布临床结果。更广泛领域的综述仍强调毒性、异质性、耐药和复杂制造是 ADC 成功尚未解决的约束。这意味着 LigaChem 的信任论证目前在试验设计和科学依据层面最强，在制造质量和市场可靠性层面较弱。因此，产品技术尽调问题不是有没有真实平台——平台确实存在——而是公开证明是否已经深到足以承销持久规模和稳定执行。[CE023, CE024, CE025, CE026, CE027, CE029]
| 控制 / 质量信号 | 状态 | 范围 | 缺口 |
|---|---|---|---|
| ClinicalTrials 注册 | 已具备 | LCB02A, LNCB74, IKS014, IKS03 | 注册证明治理，不证明疗效 |
| FDA 监管药物标记 | 引用的试验 API 中已具备 | 当前人体研究 | 不能替代制造质量披露 |
| 标准化疗效 / 安全框架 | 已具备 | RECIST、Lugano、ECOG、器官功能筛查、不良事件收集 | 尚无公开成熟产出数据 |
| 类别特异排除标准 | 已具备 | ILD/肺炎、既往载荷暴露、神经病变、眼部风险 | 显示风险意识，也凸显安全窗偏窄 |
| 制造与 QA 指标 | 公开材料未保留 | CMC、GMP、批放行、偏差历史 | 平台价值判断的重大尽调阻碍 |
公开信任证据目前以方案为中心，而不是以商业化或制造为中心。
[CE023, CE024, CE025, CE026, CE029, CE038]06客户
6.1 客户是谁：交易对手，而非终端用户
LigaChem 当前客户群最好用生物技术授权视角来看。公司还没有把成品药卖给医院、支付方或消费者。它卖的是 ADC 平台准入、单个产品候选物准入，或共同开发权。官方公司材料明确把伙伴模式定义为联合研究、共同开发和授权。这让客户定义异常清楚：直接买方是愿意为独家权利付费的制药和生物技术组织；直接用户是把资产继续向前推进的伙伴 R&D 和临床开发团队；经济支付方则是同一批交易对手，通过首付款、里程碑和未来特许权使用费付款。 这个客户群已经足够宽，可以有意义地分层。有 Ono、Janssen 这样的产品授权伙伴；有 SOTIO、Ono 这样的平台授权伙伴；有 Iksuda 加 Fosun 这样的共同开发和权利拆分关系；也有 CStone、NextCure 这样的伙伴开发关系。官方历史页面显示，这些不是为了撑门面的零散名字；伙伴名单跨越多年和多种资产类型。含义是，LigaChem 在全球 ADC 生态里已经获得真实的 BD 市场采纳。未解问题不是交易对手是否存在，而是其经济性有多集中。[CU001, CU002, CU003, CU004, CU005, CU006]
| 分群 | 买方 / 用户 / 付款方 | 用例 | 规模 | 收入 / 战略价值 | 缺口 |
|---|---|---|---|---|---|
| 产品授权药企合作伙伴 | 买方：BD/R&D；用户：临床开发组织；付款方：首付款 / 里程碑交易对手 | 授权指定 ADC 资产用于全球开发 | 锚定的实名客户包括 Ono 和 Janssen | 可产生很大的里程碑池和版税 | 无公开续约或满意度指标 |
| 平台授权肿瘤合作伙伴 | 买方：合作伙伴发现 / 组合团队；用户：合作伙伴 ADC 团队；付款方：平台费和里程碑 | 将 ConjuAll 和连接子-载荷技术栈用于合作伙伴选定靶点 | 实名证据包括 SOTIO 和 Ono | 验证平台不只靠单一分子成立 | 单个靶点的商业深度仍不透明 |
| 权益拆分的区域合作伙伴 | 买方：区域生物技术公司 / 药企；用户：本地临床 / 商业团队；付款方：按地区划分的被许可方 | 在地区权益拆分下开发同一资产 | Fosun 覆盖大中华区；Iksuda 覆盖 LCB14 的大中华区 / 韩国以外地区 | 不必完全自建全球化，也能扩大覆盖 | 造成客户经济性碎片化 |
| 共同开发 / 股权绑定合作伙伴 | 买方：合作伙伴管理层 + 投资人；用户：联合管线团队；付款方：授权与股权资本组合 | 围绕多个资产和控制权加深关系 | Iksuda 是最清晰案例 | 相比简单对外授权，可捕获更多下游价值 | 抬高治理和执行复杂度 |
| 临床合作伙伴 | 买方：合作伙伴 R&D / 转化团队；用户：试验运营方 | 推动合作资产完成 IND 和 1 期活动 | NextCure 和 CStone 提供当前证据 | 商业化前就形成外部验证 | 经济性和时间点仍可能高度不均 |
终端患者和试验中心是合作资产的下游用户，但在 LigaChem 现有模式中，它们不是直接经济客户。
[CU001, CU002, CU003, CU006, CU020]客户旅程是长周期药企合作伙伴流程，不是自助式 SaaS 动作。
[CU002, CU006, CU012, CU023]6.2 具名客户证明：最强证据来自里程碑与试验进展
具名证明集比普通初创公司 logo 页强得多，因为多个交易对手已经进入硬性运营里程碑。Ono 是最干净的例子。2024 年一揽子交易覆盖 LCB97 和更广泛的 ConjuAll 平台权利；到 2026 年 7 月，这段关系已经推进到首例患者给药，并触发估计超过上一年收入 10% 的里程碑。SOTIO 是另一个高质量证明点：2021 年协议覆盖最多 5 个项目，将下游开发和商业化责任放在 SOTIO 一侧；到 2026 年初，SOT106 进展已经带来另一笔里程碑。 Iksuda 和 CStone 增加了多年连续性和运营深度。Iksuda 的关系覆盖 Greater China 和 South Korea 之外 LCB14 的全球权利，之后进入首例患者临床活动，最终又形成战略股权绑定，把 LigaChem 拉近管理参与。CStone 将 CS5001 从 2020 年授权推进到 2024 年末 Phase 1b。Janssen 和 NextCure 也有意义，只是本次保留的公开证据对新近下游里程碑较薄。总体上，最好的规则很简单：客户关系只有从合同文字跨入试验登记、患者给药或里程碑经济性，才值得承销。LigaChem 已经有多个关系做到了。[CU007, CU008, CU009, CU010, CU011, CU012]
| 客户 | 细分类型 | 部署 / 使用场景 | 生产化 / 试点 | 结果 | 限制 |
|---|---|---|---|---|---|
| Ono Pharmaceutical | 产品 + 平台合作方 | LCB97 全球权益，加上多靶点 ConjuAll 合作 | 签约后，已首例患者给药并触发里程碑 | 确认交易已推进到临床经济性 | 具体里程碑金额未披露 |
| SOTIO Biotech | 平台合作方 | 最多五个针对实体瘤、使用 LCB 平台的 ADC 项目 | 签约后，已取得里程碑并推进到 IND 前 | 显示多项目平台被采用，且可重复变现 | 仍缺人体疗效证据 |
| Iksuda Therapeutics | 权益拆分 + 股权联动合作方 | 大中华区 / 韩国以外全球 LCB14 / IKS014，以及 LCB73 管线扩展 | 活跃 1 期项目，后续又加深股权关系 | 留存样本中最强的先落地再扩张案例 | 满意度和合同经济性仍不透明 |
| CStone Pharmaceuticals | 产品授权合作方 | CS5001 / LCB71 ROR1 ADC 在韩国以外开发 | 1b 期临床开发 | 显示 2020 年交易延续多年，并推进到后期人体数据 | 对 LigaChem 的收入贡献未披露 |
| Janssen / Johnson & Johnson | 大型药企产品合作方 | LCB84 Trop2 ADC 开发和商业化权益 | 签约阶段为 1/2 期合作 | 得到顶级全球药企买方验证 | 此处未保留新的下游里程碑证据 |
| NextCure | 临床合作伙伴 | LNCB74 B7-H4 ADC 处于 1 期 | 临床开发阶段 | 确认另一个活跃的合作临床项目 | 此处未保留公开经济条款 |
在这一商业模式下，「生产化」指活跃临床开发或里程碑执行，而不是消费级规模化商业部署。
[CU007, CU008, CU010, CU012, CU016, CU018]公开验证从历史 BD 广度收窄到较小一组交易对手，且这些对手有新的运营里程碑。
这个漏斗衡量证据质量和成熟度，不衡量客户总数。
[CU005, CU021, CU022, CU026]具名客户证据在保留样本中的强度并不相同。
[CU018, CU019, CU026, CU029, CU030, CU031]6.3 持久性、扩张与集中度
客户章节最难的是持久性，因为 LigaChem 是生物技术授权方，不是订阅软件公司。保留来源没有提供按群组划分的客户数、续约率、GRR、NRR，甚至没有伙伴收入拆分。这迫使分析转向代理指标。最佳可用代理指标，是从初始交易到后续里程碑或更深范围的关系连续性。按这个标准，平台表现好于平均水平。Iksuda 从授权扩展到股权和管线控制。Ono 先是单资产授权，后来又买入多靶点平台准入。SOTIO 从平台协议推进到后续里程碑证明。CStone 将授权资产推进到更后期临床阶段。这些都说明，客户在初始新闻稿之后仍保持投入。 但持久性不等于集中度透明。公开证明明显集中在少数交易对手和资产上。由于这个模型的经济性不连续且由里程碑驱动，一项研究延迟或一个伙伴重新排序管线，都可能对已确认收入造成放大影响。2026 年融资给 LigaChem 更大自研自由度，也反过来凸显这个缺口：公司看起来正在增加内部可选性，正因为单靠伙伴主导变现不足以抹平收入模型。客户群在战略质量上强，但还不够宽、也不够透明，不能排除集中度风险。[CU023, CU024, CU025, CU026, CU027, CU028]
| 指标 | 值 / 空值 | 细分 | 置信度 | 尽调要求 |
|---|---|---|---|---|
| 续约率 | null | 所有合作方细分 | 高 | 按交易对手索取续约和期权行权历史 |
| NRR / GRR | null | 所有合作方细分 | 高 | 索取合作方层面的收入分群和版税穿透 |
| 多年连续性代理指标 | 选定锚定客户已出现 | Ono、SOTIO、Iksuda、CStone | 高 | 把每个合作方从签约日追踪到最新运营里程碑 |
| 客户满意度证据 | null | 所有合作方细分 | 中 | 索取签约后推荐语，或安排交易对手尽调访谈 |
| 重复变现证据 | 已出现但稀疏 | 具体为 Ono 和 SOTIO | 中 | 按合作方和资产索取里程碑历史 |
| 流失 / 终止关系 | 留存材料中为空 | 所有合作方细分 | 中 | 索取已终止或不活跃合作关系历史 |
目前耐久性靠连续推进和里程碑做代理，而不是已披露的分群经济性。
[CU026, CU027, CU028, CU031]| 扩张驱动因素 | 集中度风险 | 影响 | 尽调路径 |
|---|---|---|---|
| 将具名资产与更广的平台权益打包的交易 | 少数战略交易对手可能主导可见经济性 | 一个交易对手延误就可能实质改变确认收入 | 索取合作方层面的收入集中度和里程碑日历 |
| 从授权落地扩展到股权或管线控制权 | 更深绑定可改善经济性，但会提高治理依赖 | Iksuda 式结构模糊客户与关联方边界 | 审查股东权利、治理和转让定价风险 |
| 同一资产按地区拆分权益 | 经济性在不同地区被切碎 | 可能让商业成功对标变复杂 | 取得 LCB14 / FS-1502 / IKS014 按资产和地区拆分的分配瀑布 |
| 客户从纯授权转向在核心资产上自研 | 如果 LigaChem 保留更多权益，未来外部交易流可能减少 | 长期价值可能提高，但近期合作面会被压缩 | 明确哪些资产仍对合作开放 |
| 以里程碑驱动，而非经常性客户变现 | 短期波动和估值敏感度上升 | 里程碑事件之间，收入可见度可能陡降 | 按客户和预计时间映射已签约但尚未触发的里程碑 |
客户章节在具名证据上最强，在集中度透明度上最弱。
[CU012, CU023, CU024, CU025, CU032, CU033]没有公开的收入留存表，因此能用的最佳持续性队列，是选定核心伙伴的连续性，而不是 NRR。
这是针对若干具名交易对手的连续性队列，它们有明确后续验证；不是收入留存队列。图中展示的是核心合作关系在后续年份是否仍公开活跃。
[CU027, CU028]6.4 这对客户群承销意味着什么
客户结论是正面但有条件的。LigaChem 显然已经获得成熟交易对手的采纳，这些对手理解 ADC 科学，也愿意把真实权利、资金和开发资源放到这些关系后面。这比泛泛的初创公司背书更强，因为客户本身就是专业买方。与此同时，承销案例依赖一组窄证明点：少数交易对手、基于里程碑的经济性，以及对满意度、集中度和长期特许权使用费转化的有限公开可见度。 实际含义是，投资人应把客户章节看作全球制药体系内部技术-市场匹配的验证，而不是平滑经常性收入的证明。最强尽调问题是伙伴层面收入暴露、期权与续约行为，以及失败或终止关系的案例。如果这些答案健康，具名客户集就会成为真正的护城河信号。如果答案弱，同一小撮交易对手就会变成集中度脆弱点。[CU031, CU034, CU035, CU036, CU037]
| 指标 | 数值 | 日期 | 来源 | 可信度 | 含义 | 缺失分母 |
|---|---|---|---|---|---|---|
| 截至 2024 年对外授权交易总数 | 15 | 2026 年报告引用的截至 2024 年累计值 | BigGo | 中 | 说明历史 BD 采用面较广 | 未拆分活跃与非活跃交易 |
| 累计披露技术出口价值 | KRW 9.6 trillion（约 $6.3B） | 2026 | BigGo | 中 | 表明理论客户价值捕获很高 | 不等同于已实现现金回款 |
| Ono 里程碑门槛 | 2025 年收入的 >10% | 2026-07 | Sedaily | 中 | 单个客户事件就可能对财务有实质影响 | 具体金额未披露 |
| SOTIO 里程碑推进 | 已收到 / 应收里程碑款 | 2026-02 | LigaChem 新闻稿 | 中 | 签约之外还能反复变现 | 金额未披露 |
| 合作方主导资产的全球临床试验证据 | 至少保留 4 项活跃人体研究 | 2026 | ClinicalTrials APIs | 高 | 客户在推进资产，不是在囤积权益 | 官方未披露全组合活跃研究数量 |
| 公开收入集中度拆分 | null | 2026 | 未保留披露 | 高 | 重大投资判断缺口 | 最大合作方占比未知 |
公开采用故事在头部 BD 数量和具名里程碑上最强，在经常性经济性和集中度可见度上最弱。
[CU005, CU009, CU011, CU015, CU022, CU026]07风险
7.1 顶层风险栈：资本更多、雄心更大，但仍有临床阶段脆弱性
LigaChem 的核心风险没有变：公司价值仍取决于 ADC 分子能否从机制可信，跨到人体疗效、耐受性和可制造可重复性。变化的是雄心规模。2026 年融资给公司更多跑道，去推进后期开发甚至自研；但同一转向也增加了投资论点破裂的路径数量。公司不再只是一个期待伙伴验证的平台销售方，而是在变成平台 + 开发的混合公司，可能需要同时管理试验执行、资本配置、CMC 准备和伙伴关系。 因此，风险栈是多维的。临床失败仍是最高严重度风险，因为当前研究仍处于早期，引用试验都没有发布结果。制造和 CMC 排在其后，因为 ADC 表现高度依赖偶联质量和可重复性，而公开质量证据很薄。伙伴和客户依赖仍高，因为若干关键资产在外部控制之下。融资风险低于融资前，但没有消失，因为公司现在在资助一条更昂贵的战略。最后，法律和 IP 保护看起来真实但不完整：活跃专利存在，但公开 FTO 可见度有限。[CR001, CR002, CR003, CR007, CR008, CR018]
临床、CMC 和资本配置风险仍是最高优先级暴露领域。
[CR002, CR007, CR015, CR020, CR025, CR030]7.2 监管、法律与临床风险：科学是真实的，证明仍然很薄
监管和临床证据一边验证平台，一边凸显风险。4 条活跃 ClinicalTrials 记录显示，多个 LigaChem 衍生项目确实进入人体测试；但它们都仍背负剂量递增逻辑、biomarker 设门槛和排除标准，这些都是治疗窗口尚不确定药物的典型特征。LNCB74 排除既往 MMAE-ADC 暴露以及肺部或眼部风险因素；LCB02A 排除既往 Topo1-payload ADC 暴露；IKS014 排除 ILD 和角膜异常。这些不是抽象担忧——它们写进了方案。没有发布结果意味着投资人仍不知道哪些项目能在商业相关剂量下同时实现疗效和耐受性。 法律图景比纯概念阶段平台更好，但仍不完整。Google Patents 记录显示，LigaChem 拥有自裂解和偶联相关的活跃专利，这是真实保护。但公开材料没有提供完整 FTO 地图、到期矩阵或纠纷历史。更广泛的 ADC 领域显然诉讼不少，就连可比偶联家族也出现诉讼标记。正确结论是，IP 是缓释项，不是完整答案。没有更深尽调时，法律 / IP 剩余风险仍为中高。[CR003, CR004, CR005, CR006, CR025, CR026]
| 规则 / 案件 / 问题 | 司法辖区 | 状态 | 可能性 | 严重性 | 缓释措施 | 剩余风险敞口 | 尽调路径 |
|---|---|---|---|---|---|---|---|
| 早期 ADC 研究出现临床疗效或安全性失败 | 美国 / 全球 | 1 期和 1/2 期项目均有活跃风险 | 高 | 严重 | 生物标志物门控、剂量递增、排除标准、合作方验证 | 在人体数据成熟前仍非常高 | 跟踪 LCB02A、LNCB74、IKS014、IKS03 的安全性 / 疗效读数 |
| 路线图资产的 IND / 试验推进遭监管延误 | 美国 / 日本 / 全球 | SOT106、LCB36、LCB58A 等较新资产存在活跃风险 | 中高 | 高 | 现有合作方网络和 2026 年融资 | 时间表滑坡可能实质改变估值时点 | 索取更新后的监管日历和门控假设 |
| 自由实施 / 专利组合不确定性 | 美国 / 全球 | 活跃专利已部分缓释，但公开信息不完整 | 中 | 高 | 已转让给 LigaChem 的活跃专利 | FTO、到期日和争议范围未知 | 取得完整专利图谱和外部律师 FTO 备忘录 |
| ADC 相关专利在邻近领域的争议 | 美国 / 全球 | 已有可见的可比诉讼标记 | 中 | 中高 | 建立自有专利组合，并在需要时谈判许可 | 更广领域仍可能带来法律费用或绕开设计压力 | 梳理偶联与载荷化学周边的竞争对手专利组合 |
| 重大事件和合同条款披露不透明 | 韩国 / KOSDAQ | 公开合规，但运营细节偏薄 | 中 | 中 | 常规自愿披露和公开备案 | 投资者仍缺交易对手、条款和或有事项细节 | 索取更完整的交易条款和里程碑文件 |
本登记表只排序公开来源可见的重大法律 / 监管问题，不能替代律师主导的尽调。
[CR001, CR002, CR003, CR025, CR026, CR027]少数根风险可能一次性传导到公司的许多环节。
[CR011, CR015, CR020, CR023, CR034, CR041]7.3 运营、伙伴与客户依赖风险
LigaChem 的伙伴模式减少了一部分直接运营负担，但制造出另一种脆弱性：价值兑现取决于许多外部组织同步前进。Ono 控制 LCB97 下游。SOTIO 控制其授权项目的研究、开发、制造和商业化。Iksuda 运行关键 HER2 和 CD19 项目，同时也与 LigaChem 处在更纠缠的战略关系中。CStone 和 NextCure 运营其他外部推进资产。实际后果是，即便 LigaChem 能展示广泛验证，只要一个或多个伙伴放慢入组、重新排序管线，或没能把早期数据转成后期投资，公司仍可能错过经济预期。 客户集中度会放大这种依赖。公开来源显示具名交易对手很强，但没有显示按伙伴划分的收入拆分、流失或里程碑时点。Ono 里程碑价值至少达到上一年收入 10%，说明可见经济性可以非常集中。IKS014 / FS-1502 在 Iksuda 和 Fosun 之间的权利拆分结构，也增加了协调和治理复杂度。这是一个多元的科学生态，但很可能还不是多元的经济生态。[CR011, CR012, CR013, CR014, CR015, CR016]
| 失效模式 | 可能性 | 严重性 | 缓释成熟度 | 剩余风险敞口 | 未解决缺口 |
|---|---|---|---|---|---|
| ADC 制造中 CMC 或批次复现失败 | 中高 | 严重 | 低中 | 高 | 未保留公开 GMP 或批放行指标 |
| 载荷 / 连接子安全窗口太窄，难以支持可行给药 | 高 | 严重 | 中 | 高 | 当前缓释停留在方案层面，还不是结果层面 |
| 全球中心招募和方案执行滑坡 | 中高 | 高 | 中 | 中高 | 多项研究需要在多国大规模入组 |
| 项目铺得过散，管理带宽过载 | 中 | 高 | 中 | 中高 | 大量合作资产和自研推进资产争夺管理注意力 |
| 如果自研推进过深，商业化准备不足 | 中 | 高 | 低 | 高 | 未保留公开上市、药物警戒或市场准入基础设施 |
公开证据缺口最大之处，运营风险也最强：CMC、商业化准备和规模化执行。
[CR007, CR009, CR010, CR024, CR039, CR040]| 依赖 | 交易对手 | 角色 | 集中度 | 失败情景 | 严重性 | 缓释措施 | 剩余风险敞口 |
|---|---|---|---|---|---|---|---|
| LCB97 下游开发 | Ono | 全球开发 / 制造 / 商业化 | 高 | 试验放慢、优先级下调，或商业化推动较弱 | 高 | 交易已推进到患者给药并收到里程碑款 | 高 |
| 多靶点平台项目 | SOTIO | 授权项目从研究到商业化 | 中高 | 项目在 IND 前或临床前信号后停滞 | 高 | SOT106 里程碑显示仍在活跃推进 | 中高 |
| HER2 / CD19 合作方生态 | Iksuda 与 Fosun | 地区权益、临床开发、战略股权纽带 | 高 | 多个权益持有人之间协调或资本错位 | 高 | 更深战略绑定可能改善控制 | 高 |
| ROR1 项目外部执行 | CStone | 韩国以外临床开发 | 中 | 后期投入没有跟随早期数据 | 中高 | 1b 期进展验证当前承诺 | 中 |
| B7-H4 项目外部执行 | NextCure | 临床开发合作者 | 中 | 1 期信号不及预期，或项目优先级被下调 | 中高 | 当前 1 期活动表明承诺仍在 | 中 |
验证平台的同一批合作方，也限制了 LigaChem 对时间表和价值兑现的直接控制。
[CR011, CR012, CR013, CR014, CR015, CR016]LigaChem 依赖一张由合作伙伴、监管方、资本方和内部专业团队织成的密集网络。
[CR011, CR012, CR013, CR023, CR031, CR034]7.4 财务与执行风险：融资买来时间，不是确定性
2026 年，财务风险明显缓和，但仍是核心问题。2025 年官方报表显示，LigaChem 还不能靠自身造血： 经营亏损超过 1000 亿韩元，经营现金流出超过 1200 亿韩元，年末现金不到 1000 亿韩元。因此，5000 亿韩元融资意义很大。但市场不能把这理解成商业模式已经跑通。独立报道显示，这笔钱将投向后期临床、监管工作、生产和商业化准备——这些正是药物开发里最烧钱的环节。公司可能只是把自己推入了成本更高的风险档位。 执行风险也由此而来。治理层面，Orion 的存在感不低，能加强监督，也会带来战略控制权的敏感性。管理层明确把毒理、安全和生产放在重点位置，这是实质性的缓释因素。招聘材料显示，公司仍依赖高度专业化的科学人才。因此，实际的出局条件很直接：安全性受挫、自主推进资产时间表滑坡、现金消耗快于预期，或任何公开迹象显示合作伙伴跟进转弱。只要这些指标保持稳定，风险画像就更可投；一旦破裂，下行估值重估会很快。[CR018, CR019, CR020, CR021, CR022, CR023]
| 角色 / 职能 | 依赖或缺口 | 可能性 | 严重性 | 缓释措施 | 尽调路径 |
|---|---|---|---|---|---|
| 科学领导力 | 需要在化学、毒理学和转化开发上持续保持优秀 | 中 | 高 | 已有具名领导层和顾问覆盖 | 验证其后期 ADC 执行履历 |
| CMC 与制造领导力 | 如果自研向后期供应深化，这一点至关重要 | 中 | 高 | 领导层页面明确列出 ADC 制造 / CMC 专长 | 索取 CMC 组织架构和外包制造监督模式 |
| 临床项目管理 | 多项全球研究和合作方接口挤压带宽 | 中高 | 高 | 合作方网络分担部分执行负荷 | 索取 PMO 架构和组合优先级排序流程 |
| 董事会监督与赞助方一致性 | Orion 相关董事会席位可能加快战略决策，也可能带来偏向 | 中 | 中高 | 内外部董事混合构成 | 审查关联方治理保护 |
| 人才管线 | 招聘流程显示依赖 PhD 级科学人才 | 中 | 中高 | 招聘流程活跃，且需要专项人才招聘 | 评估留任、继任与关键人物风险敞口 |
公开可见的专业能力降低了人员风险，但后期执行还需要更多组织层面的证据，公开来源目前给不出。
[CR030, CR031, CR032]| 风险 | 可监测触发信号 | 阈值 / 事件 | 行动含义 |
|---|---|---|---|
| 临床安全性失败 | LCB02A 或 LNCB74 出现严重非预期毒性 | 出现剂量限制性模式，或研究暂停 / 方案大幅收紧 | 重新评估平台治疗窗主张 |
| 资本充足性 | 现金消耗增速超过里程碑款流入 | 核心读数或商业化路径清晰前，又需要大额融资的证据 | 提高稀释和融资风险折扣 |
| 合作伙伴依赖 | 具名核心伙伴降低或暂停重点项目优先级 | 里程碑节奏消失，或被移出伙伴管线 | 下调外部验证价值及兑现时点假设 |
| CMC 准备度 | 自主开发加深，但制造或质量体系未披露进展 | 后期开发野心推进，却没有新的 CMC 证据 | 将战略转向视为资源不足 |
| 执行摊子过大 | 路线图资产较 2026-2027 年计划明显延后 | LCB36 或 LCB58A 未按期 IND / 启动 1 期，或 LCB02A 大幅延误 | 下调管理层执行信心 |
论点最脆弱的地方，是安全性、时间、资本和伙伴行为等多重风险叠加。
[CR020, CR021, CR034, CR041, CR042]08估值
8.1 投资论点和反论点都必须先看价格敏感性
LigaChem 不是一家可以轻描淡写带过的公司。它有真正的 ADC 平台、扎实的合作伙伴验证、多个人体试验项目，也拿到了足以支撑更激进战略的融资，而许多同行负担不起。市场给它溢价，有真实理由。大型药企和专业生物科技交易对手反复选择该平台，2026 年再融资和持续里程碑也说明，公司不只是一个科学项目。因此，正面论点很清楚：LigaChem 具备战略价值、产品选择权和足够的市场关注度，值得投资者继续盯住。 反论点同样重要。当前估值已经假设，很大一部分选择权会转成未来价值。市值约 4.125 万亿韩元，而 2026 年收入预期只有约 2840 亿韩元，市场并没有按近期基本面给一家亏损型生物科技公司定价，而是在给未来管线和平台成功定价。如果数据和执行很快降风险，这套定价可以成立；如果投资者把理论里程碑上限、分析师目标价空间或战略股东背书误认为已经验证的商业经济性，就会危险。本章第一件事不是判断公司好不好，而是判断当前价格是否已经替投资者预支了太多未来。[CV001, CV002, CV003, CV005, CV006, CV007]
| 论点 | 什么会改变判断 |
|---|---|
| 拥有真实平台可选性，并获蓝筹伙伴验证 | 若当前重点资产拿出人体证据并提高 CMC 可见度，判断会增强 |
| 2026 年融资显著降低短期偿付风险 | 若现金消耗再加速，或关键拐点前还需融资，判断会削弱 |
| 公开市场已计入相当多的未来成功 | 若价格压缩，或证据改善快于市场预期，判断会改善 |
| 没有已上市旗舰产品，也没有公布重点试验结果，仍是核心反论点 | 若自主推进资产出现人体概念验证数据，反论点会削弱 |
核心争论不是抽象公司质量，而是当前报价里已经埋入了多少成功。
[CV006, CV007, CV010, CV011, CV029, CV030]当前结论来自两股力量的碰撞：战略质量确实扎实，但公开市场入场价仍偏贵。
[CV010, CV011, CV029, CV030, CV033]IC 风格摘要，展示当前证据在最关键维度上的得分。
[CV009, CV010, CV011, CV030, CV032, CV033]8.2 融资和可比公司支撑溢价，但不是无条件溢价
公开可比公司给出两种方向。一方面，ADC Therapeutics、Sutro Biopharma 等上市开发阶段 ADC 同行的市值，比 LigaChem 低数亿美元。CStone 虽然是已上市的亚洲肿瘤生物科技公司，商业和临床背景更宽，但按当前市值筛选仍低于 LigaChem。这提醒投资者：即便是真实的 ADC 故事，公开市场也可能极度苛刻。另一方面，战略并购锚点显示了品类头部能拿到的价格：Seagen 约 430 亿美元，ImmunoGen 在获批产品和后期验证之后达到每股 $31.26。这些结果巨大，但买家并不是为未经验证的故事买单。 LigaChem 夹在这两端之间。它显然强于普通早期平台公司；从合作伙伴验证和选择权价值看，也可能强于部分上市同行。但相比已获批产品驱动的战略收购，它的降风险程度明显更低。因此，混合可比组才是唯一诚实的方法。当前公开价格为何显得贵而非疯狂，也由此能解释：公司配得上溢价，但这个溢价不能脱离证据到不再受证据约束。[CV013, CV014, CV015, CV016, CV017, CV018]
| 可比对象 | 指标 | 倍数 / 估值 / 状态 | 参考价值 | 局限 |
|---|---|---|---|---|
| LigaChem 当前公开报价 | 市值与远期销售额 | ~KRW 4.125T 市值；约 14.5x 2026 年销售预测 | 最好的实时入场锚点 | 收入基础仍以授权为主，且受事件驱动 |
| ADC Therapeutics | 公开市场市值 | ~$0.14-0.15B | 说明公开市场对 ADC 叙事可以很冷 | 资产组合和商业化轮廓不同 |
| Sutro Biopharma | 公开市场市值 | ~$0.40-0.41B | 有用的平台型公开可比公司 | 仍不能直接类比 LigaChem 的伙伴模式 |
| CStone Pharmaceuticals | 亚洲上市肿瘤生物科技市值 | ~HKD 6.9B 至 8.4B | 区域上市生物科技语境比纯美国同业更接近 LigaChem | 商业模式和产品组合不同 |
| Pfizer / Seagen 收购 | 战略并购 EV | 企业价值约 $43B | 显示世界级已获批 ADC 产品组合的上限 | 去风险程度远高于 LigaChem |
| AbbVie / ImmunoGen 收购 | 战略并购与获批产品锚点 | 以 $31.26/股收购，含已获批 ELAHERE 和后期管线 | 显示产品获批和标签扩展可见后，价值会抬升 | 同样，比 LigaChem 阶段晚得多 |
这组混合可比对象是优点，不是缺陷：更干净的可比集看起来更精确，但更不诚实。
[CV001, CV003, CV013, CV014, CV015, CV016]在当前验证阶段，用情景区间比给出单点估值更可信。
情景区间对证据敏感，不是 DCF 输出。基准情景的上沿大致止于当前报价，因为市场看起来已把相当多未来成功计入价格。
[CV001, CV003, CV023, CV033, CV034, CV035]8.3 建议：除非价格或证据改善，否则跟踪 / 继续研究
按当前报价，合适的建议是跟踪 / 继续研究，而不是买入。这个建议不是否定公司，而是承认当前估值已经假设投资者会拿到一套高质量的未来证据包：领先自主推进资产的人体数据、合作伙伴继续兑现里程碑、可信的 CMC 准备，以及足以在不遭遇惩罚性稀释前提下撑到这些节点的现金。这套未来证据包可能会到来。但在到来之前，激进买入股票就是提前为相当多的成功付费。 价格敏感性也由此而来。如果股价大幅压缩，而平台质量或融资位置没有同步恶化，回报逻辑会很快变得更有吸引力。如果价格在缺少人体数据或 CMC 降风险的情况下继续上涨，不对称性会变差。多头情景真实存在；基准情景仍比市场似乎期待的更慢、更有条件；空头情景也不难想象，因为临床、烧钱和合作伙伴依赖风险都还活着。因此，中等信心和高风险是纪律化结论，不是回避判断。[CV027, CV028, CV029, CV030, CV031, CV032]
| 建议 | 信心 | 风险评级 | 估值立场 | 决策含义 |
|---|---|---|---|---|
| 跟踪 / 继续研究 | 中 | 高 | 估值偏贵 / 对证据敏感 | 没有更好数据或更好入场价，不追当前价格 |
| 有条件上调路径 | 中，证据改善后可升至高 | 高，有证据后可降至中 | 需要更强的人体、CMC 和经济性证据 | 保持主动尽调，而不只是被动观察 |
建议取决于证据和价格，不是泛泛的质量打分。
[CV030, CV031, CV032, CV033]| 情景 | 假设 | 估值 / 回报逻辑 | 关键风险 | 概率信号 |
|---|---|---|---|---|
| 牛市 | LCB02A 早期人体数据有进展，合作伙伴里程碑持续兑现，CMC 放大路径可信 | 支撑价值显著高于当前市值，并更接近战略溢价逻辑 | 仍暴露于执行和稀释风险 | 低至中 |
| 基准 | 平台仍有价值，但去风险更慢，现金消耗仍大 | 当前报价已覆盖大部分近期合理价值；上行需要耐心 | 证据、时点和可比公司匹配度仍不完美 | 中至高 |
| 熊市 | 临床延误、伙伴进度滑坡、现金消耗加重，或估值倍数向公开同业压缩 | 价值明显低于当前报价，事后看显得透支 | 临床和融资挫折可能快速叠加 | 中 |
情景逻辑对里程碑和概率敏感，因为单一倍数法对当前阶段过于粗糙。
[CV034, CV035, CV036, CV039, CV042]少数几个待解问题，主导了可能价值区间。
影响条按等级展示，不是统计模型；它们排序的是哪些尽调结论最能撬动估值。
[CV034, CV036, CV039, CV040, CV042]8.4 最终尽调问题和推翻论点的触发器
最后一步要明确什么会改变判断。上调评级需要更好证据，或更好价格。更好证据意味着：LCB02A 或其他优先资产拿出清晰早期人体数据，合作伙伴层面的经济条款显示真实现金转化质量，CMC 证据支撑未来放大生产，并且自主开发资产的上市或后期准备能看得见。更好价格意味着，市场让出部分当前选择权溢价，而核心论点没有破裂。 到 2027 年，主要推翻触发器同样直接。如果领先项目安全性或疗效信号令人失望，如果 2026 年现金弹药消耗快于预期，或合作伙伴势头停滞，当前溢价可能很快压缩到公开同行区间。反过来，如果公司能在消耗资本之前，更快把平台选择权转成已降风险的产品价值，今天的溢价就会更站得住。到那之前，投资逻辑仍然成立，但按当前价格还不到高信念级别。[CV039, CV040, CV041, CV042]
| 触发因素 | 阈值 | 对论点的传导 | 行动含义 |
|---|---|---|---|
| 重点资产安全性或疗效令人失望 | LCB02A 或 LNCB74 人体数据出现明确负面信号 | 削弱平台溢价叙事和自主开发上行空间 | 立场转向回避 / 低配 |
| 资金续航恶化 | 有证据显示 2026 年融资不足以支撑到关键拐点 | 抬高稀释风险，降低战略期权价值 | 要求更低入场价或更强融资结构 |
| 伙伴动能停滞 | 里程碑放缓、伙伴管线地位下降，或交易对手降低资产优先级 | 削弱护城河和客户验证支柱 | 下调牛市和基准情景概率 |
| 自主开发加深，但 CMC 证据仍缺位 | 虽有后期开发野心，却看不到制造准备度升级 | 让溢价更难自圆其说 | 将战略转向视为资源不足 |
| 没有证据，价格先涨 | 报价在没有去风险证据下明显高于当前水平 | 进一步把风险收益不对称推向不利于新投资者 | 仅保留在观察名单 |
关键放弃标准大多可从公开数据和后续尽调中观察，因此建议具备可执行性。
[CV038, CV039, CV042]| 主题 | 缺失证据 | 为什么重要 | 负责人或尽调路径 |
|---|---|---|---|
| 伙伴层面经济条款 | 收入分成、里程碑日程、版税时点、交易对手敞口 | 区分真实变现质量与理论交易价值 | 财务 + BD 尽调，并审阅合同 |
| CMC 与上市准备度 | 制造网络、QA 指标、放行历史、上市规划 | 判断自主开发溢价是否可信 | 运营 + 技术尽调 |
| 自由实施与 IP 范围 | 全组合专利族、到期日、引进许可义务、挑战历史 | 检验护城河是否守得住，还是只是看起来可行 | IP 律师尽调 |
| 分析师模型假设 | 目标价背后的成功概率、WACC、收入爬坡和终值逻辑 | 避免过度依赖不透明的公开目标价 | 收集卖方报告并重建模型 |
| 通往关键拐点的资本路径 | 各资产现金用途，以及到达决定性读数所需最低融资 | 厘清当前溢价是否应纳入未来稀释 | 管理层尽调和情景模型 |
如果这些尽调问题都能良好收口，即便业务本身没有剧烈变化，建议也可以上调。
[CV040, CV041, CV042]免责声明
本报告是基于公开证据的尽调快照，不构成投资建议。关键财务、法律、技术和合同事实仍未公开；作出任何投资决定前，应直接向管理层并通过一手文件核验。
证据索引
| 编号 | 陈述 | 可信度 | 来源 |
|---|---|---|---|
| CO001 | LigaChem Biosciences is a clinical-stage biopharmaceutical company focused on innovative medicines for diseases with high unmet medical need. | 高 | SO002, SO015 |
| CO002 | Founder-chairman Yong-Zu Kim says he founded LigaChem Biosciences in 2006. | 高 | SO005, SO015, SO016 |
| CO003 | The company headquarters are in Daejeon, South Korea at 10, Gukjegwahak 10-ro, Yuseong-gu. | 高 | SO006, SO015, SO016 |
| CO004 | LigaChem Biosciences is publicly listed on KOSDAQ under ticker 141080. | 高 | SO003, SO009, SO015, SO016 |
| CO005 | The official company history says LigaChem listed on KOSDAQ through an IPO in 2013. | 中 | SO003 |
| CO006 | Official overview materials say the company concentrates its R&D on ADC and immuno-oncology programs using a next-generation ADC platform that combines medicinal chemistry with biologics. | 高 | SO001, SO002 |
| CO007 | The public leadership pages and Yahoo profile identify Sejin Park as CEO and President. | 高 | SO004, SO015 |
| CO008 | Yong-Zu Kim remains chairman while Sejin Park appears to run day-to-day operations as CEO, preserving founder influence alongside delegated execution. | 中 | SO004, SO005, SO011 |
| CO009 | The company changed its name from LegoChem Biosciences to LigaChem Biosciences in March 2024. | 高 | SO003, SO015 |
| CO010 | PAN Orion became LigaChem's largest shareholder in 2024. | 中 | SO003, SO018 |
| CO011 | The governance page lists Orion-related executives In Chul Heo, Suhwon Tam, and Yong Su Kwon as internal directors or recent board appointees. | 中 | SO011 |
| CO012 | The same governance page shows two external directors and reports 96% board attendance with 13 meetings in the latest disclosed year. | 中 | SO011 |
| CO013 | On 2026-06-26 LigaChem announced a KRW 500 billion direct investment led by the National Growth Fund and related investors. | 高 | SO012, SO014, SO018, SO019, SO020, SO024, SO025 |
| CO014 | The 2026 financing consists of KRW 170 billion of convertible bonds and KRW 330 billion of convertible preferred shares with 10-year tenor. | 高 | SO012, SO013, SO018, SO019 |
| CO015 | Korea Development Bank's managed strategic-industry fund contributes KRW 250 billion while Pan Orion and another financial investor provide the remaining KRW 250 billion. | 中 | SO018, SO019 |
| CO016 | Media and company materials frame the deal as both the first direct National Growth Fund investment in a biotech company and the first direct investment by the fund into a listed company. | 高 | SO012, SO019, SO020, SO024 |
| CO017 | The investor Q&A says the issue price was determined by statutory capital-markets formulas and no discount was applied. | 高 | SO012, SO013 |
| CO018 | The same Q&A says conversion rights begin only after 24 months and one-year lockup or split restrictions apply to the issued securities. | 高 | SO012, SO013 |
| CO019 | Company materials say LigaChem already held roughly KRW 450 billion of cash before the new financing. | 高 | SO013, SO018 |
| CO020 | Seoul Economic Daily reported that the new money would take combined cash and cash equivalents into the KRW 900 billion range. | 中 | SO020 |
| CO021 | Management said the new capital is for R&D and late-stage clinical development rather than for M&A or control transactions. | 高 | SO012, SO013, SO019, SO020 |
| CO022 | Management said the financing adds an in-house late-stage development option without replacing the company's licensing-out strategy. | 高 | SO013, SO018, SO019 |
| CO023 | Vision 2030 still describes the business model through roughly 2027 as early-stage out-licensing combined with value inflection from advancing selected internal assets into phase 1/2. | 中 | SO007 |
| CO024 | The official history records a 2023 licensing partnership with J&J for the TROP2-targeted ADC LCB84. | 中 | SO003, SO022, SO023 |
| CO025 | BioSpace and Pharmaceutical Technology say the J&J/Janssen LCB84 deal is worth up to $1.7 billion, including a $100 million upfront payment and a $200 million option exercise fee. | 中 | SO022, SO023 |
| CO026 | The official history records a 2024 package deal with Ono Pharmaceutical for LCB97 and a multi-target ADC platform license. | 中 | SO003 |
| CO027 | The official history records a 2022 licensing partnership with Amgen for multi-target ADC research and development. | 中 | SO003 |
| CO028 | The official history records a 2022 co-development partnership with NextCure on a B7-H4 ADC. | 中 | SO003 |
| CO029 | The official history says LigaChem repeatedly won World ADC Awards recognition for its platform between 2021 and 2025. | 中 | SO003 |
| CO030 | The official history says LCB97/ONO-7429 received phase 1 IND approval in Japan in April 2026. | 中 | SO003 |
| CO031 | The official history says LCB02A received U.S. phase 1/2 IND approval in May 2026. | 中 | SO003 |
| CO032 | The official history says LNCB74 received U.S. phase 1 IND approval in December 2024. | 中 | SO003 |
| CO033 | Korea Biomedical Review reported that LigaChem had completed 14 global licensing deals, 11 of them in ADCs, by June 2026. | 中 | SO018 |
| CO034 | The same Korea Biomedical Review article said the company was running eight global clinical trials, including a phase 3 LCB14 study led by Fosun Pharma. | 中 | SO018 |
| CO035 | Public company pages disclose a Daejeon headquarters and a separate Seoul office for pharmaceutical sales. | 高 | SO006, SO016 |
| CO036 | On runDate 2026-08-07 the official stock page showed a KRW 113,200 share price with a 52-week high of KRW 225,000 and a 52-week low of KRW 76,900. | 中 | SO009 |
| CO037 | GlobalNewstop reported that LigaChem's shares fell 8.28% on the 2026-06-26 funding day and remained roughly half the 52-week high, indicating the raise did not trigger an immediate rerating. | 中 | SO021 |
| CO038 | The official disclosure page on 2026-08-07 still highlighted completed issuance results from 2026-07-24 and a 2026-07-09 LCB97 milestone-fee receipt. | 中 | SO010 |
| CO039 | LigaChem filed a Notice on Investor Relations with Korean DART on 2026-06-30, showing an active listed-company communication cadence after the June financing. | 中 | SO017 |
| CM001 | LigaChem's relevant market spans both downstream ADC therapeutics and the upstream platform-licensing market that sells ADC assets into larger pharma pipelines. | 高 | SM001, SM002, SM003, SM024 |
| CM002 | The core market should include approved ADC product sales, clinical-development spending, and licensing demand tied to oncology ADC assets rather than all oncology drug spend. | 中 | SM003, SM005, SM006 |
| CM003 | The core market should exclude conventional chemotherapy, unconjugated monoclonal antibodies, cell therapy, and generic biologics except where they act as substitutes or comparison sets. | 中 | SM004, SM012 |
| CM004 | Grand View Research estimated the global ADC market at USD 11.29 billion in 2023 and projected USD 24.01 billion by 2030. | 中 | SM004 |
| CM005 | The Business Research Company estimated the ADC market at USD 20.28 billion in 2026 and USD 46.95 billion by 2030. | 中 | SM005 |
| CM006 | Mordor Intelligence projected ADC market growth from USD 20.12 billion in 2026 to USD 71.55 billion by 2031. | 中 | SM007 |
| CM007 | Fairfield Market Research projected the ADC market at USD 16.80 billion in 2026 and USD 35.99 billion by 2033. | 中 | SM008 |
| CM008 | Research and Markets projected USD 13.77 billion of incremental ADC market growth during 2025-2030 at a 15.7% CAGR. | 中 | SM006 |
| CM009 | The spread between roughly USD 16.8 billion and USD 20.3 billion for 2026 shows that public ADC TAM estimates are methodology-sensitive and should be treated as a range, not a single canonical number. | 中 | SM005, SM006, SM007, SM008 |
| CM010 | Grand View defined ADCs as antibodies linked to cytotoxic drugs that aim to improve efficacy and reduce systemic toxicity relative to conventional chemotherapy. | 中 | SM004 |
| CM011 | The Business Research Company segments ADC end users into hospitals, clinics, and other care settings. | 中 | SM005 |
| CM012 | Mordor Intelligence said hospitals generated 51.55% of ADC revenue share in 2025. | 中 | SM007 |
| CM013 | Fairfield said breast cancer accounted for 40.0% of the ADC market in 2026. | 中 | SM008 |
| CM014 | Grand View said the breast-cancer segment dominated ADC revenue in 2023 with a 47.76% share. | 中 | SM004 |
| CM015 | Grand View said HER2-targeted ADCs held the largest target segment share in 2023. | 中 | SM004 |
| CM016 | Fairfield said Enhertu represented 28.0% of the ADC market in 2026 and remained the broadest-indication active ADC franchise. | 中 | SM008 |
| CM017 | Mordor said topoisomerase I inhibitor payloads accounted for 53.53% of 2025 ADC value and cleavable linkers 72.15%. | 中 | SM007 |
| CM018 | Grand View likewise said cleavable linkers held 72.43% of ADC technology share in 2023. | 中 | SM004 |
| CM019 | Research and Markets identified rising cancer incidence, precision-oncology shift, linker and payload advances, and specialized manufacturing investment as core growth drivers. | 中 | SM006 |
| CM020 | The Business Research Company said rising clinical-trial activity is a core growth driver for the ADC market. | 中 | SM005 |
| CM021 | Mordor said 431 active ADC studies and 83 phase 3 trials were visible by January 2026, illustrating the scale of the development engine behind the market. | 中 | SM007 |
| CM022 | Fairfield said repeated label expansion in HER2 and TROP2 indications is broadening the addressable patient pool and moving ADCs toward earlier treatment lines. | 中 | SM008 |
| CM023 | Experimental Hematology & Oncology's 2026 AACR review said next-generation ADCs are evolving toward dual-payload, multispecific, and immune-integrated platforms designed to overcome heterogeneity, resistance, and systemic toxicity. | 中 | SM011 |
| CM024 | ADC Review's 2026 coverage described bispecific and novel ADCs as a rapidly expanding solid-tumor development wave. | 中 | SM013, SM014 |
| CM025 | The 2025 Frontiers review said ADCs still face systemic toxicity, drug resistance, tumor heterogeneity, and complex manufacturing processes despite their targeting advantages. | 中 | SM012 |
| CM026 | FDA's clinical-pharmacology guidance for ADCs explicitly requires bioanalytical methods, dosing strategy, exposure-response work, QTc, immunogenicity, and DDI analysis, making development more complex than simpler biologics. | 中 | SM010 |
| CM027 | Fairfield said HPAPI-qualified ADC manufacturing sites are scarce, command roughly 30-40% cost premiums, and can impose 18-to-24-month lead times for new entrants. | 中 | SM008 |
| CM028 | Pfizer CentreOne emphasizes that ADC manufacturing requires cGMP facilities and frequent inspections by a wide set of global regulators, reinforcing the sector's manufacturing-compliance burden. | 中 | SM022 |
| CM029 | Grand View said high production and research costs create reimbursement pressure because ADCs are more expensive than conventional chemotherapy or plain monoclonal antibodies. | 中 | SM004 |
| CM030 | NICE's Enhertu decision said cost-effectiveness uncertainty and an unacceptable NHS price can block routine reimbursement even for clinically important ADCs. | 中 | SM017 |
| CM031 | NICE guidance TA992 states that commissioners and providers must fund recommended use, showing that public-payer budget ownership is central to downstream ADC adoption. | 中 | SM018 |
| CM032 | PADCEV Support Solutions says coverage and reimbursement vary by payer, patient, and setting of care and must be verified before treatment starts. | 中 | SM019 |
| CM033 | Grand View said North America accounted for 52.54% of ADC revenue in 2023. | 中 | SM004 |
| CM034 | Fairfield said North America generated USD 6.72 billion in 2026 while Asia Pacific was set to grow at an 11.7% CAGR. | 中 | SM008 |
| CM035 | Mordor said North America's leadership is reinforced by Medicare coverage of outpatient ADC infusions and concentrated manufacturing capacity. | 中 | SM007 |
| CM036 | Fairfield highlighted Japan, South Korea, and China as Asia-Pacific markets where oncology reimbursement frameworks are expanding to accommodate targeted therapies. | 中 | SM008 |
| CM037 | Roche's 2026 ASCO update said it was presenting data from nine approved and investigational medicines including bispecific antibodies and ADCs, indicating that large incumbents now treat ADCs as core oncology modalities. | 中 | SM016 |
| CM038 | Roche's pipeline and BMS' modality pages show ADCs and other targeted modalities are embedded in mainstream oncology-development strategy rather than treated as fringe experiments. | 中 | SM015, SM023 |
| CM039 | The Business Research Company said Pfizer's USD 43 billion Seagen acquisition was aimed at strengthening oncology leadership through next-generation ADCs. | 中 | SM005 |
| CM040 | For LigaChem specifically, the immediate buyer is usually a large pharma or biotech partner licensing an ADC asset, while the downstream user is the oncologist and the downstream payer is an insurer or national health system. | 高 | SM002, SM003, SM011, SM018, SM019 |
| CP001 | LigaChem presents itself as a clinical-stage biopharmaceutical company whose R&D focus is next-generation ADCs and related oncology modalities. | 中 | SP001 |
| CP002 | LigaChem publicly emphasizes joint research, co-development, and licensing with global partners rather than direct commercialization today. | 中 | SP002 |
| CP003 | LigaChem's most relevant competitor set therefore starts with approved ADC franchise owners and platform licensors rather than only same-country early-stage biotechs. | 高 | SP001, SP002, SP022, SP023 |
| CP004 | ENHERTU is the strongest public benchmark in ADC because official product pages show unusually broad label breadth across multiple HER2-defined tumor settings and BioMed Nexus calls it the best-selling ADC. | 高 | SP005, SP006, SP024 |
| CP005 | Official ENHERTU patient and HCP sites show the franchise already spans early breast cancer, metastatic breast cancer, HER2-low or ultralow breast cancer, HER2-mutant NSCLC, gastric cancer, and HER2-positive solid tumors. | 高 | SP005, SP006 |
| CP006 | Pfizer's scale and the Seagen acquisition leave it positioned as a top ADC incumbent rather than a legacy lymphoma-only player. | 中 | SP003, SP024 |
| CP007 | BioMed Nexus describes Pfizer's roughly $43 billion Seagen acquisition as the defining ADC deal because it transferred multiple approved ADCs and a deep pipeline into big pharma hands. | 中 | SP024 |
| CP008 | ADCETRIS remains clinically important because its official patient site says it is approved across eight lymphoma indications and backed by more than a decade of clinical data. | 中 | SP007 |
| CP009 | ADCETRIS' HCP site carries a boxed warning for progressive multifocal leukoencephalopathy and extensive hematologic, pulmonary, dermatologic, and gastrointestinal precautions. | 中 | SP008 |
| CP010 | TRODELVY is a broader commercial competitor than a pipeline-only peer because its patient and HCP support sites show marketed use, ordering data, and structured financial-assistance workflows. | 高 | SP009, SP010 |
| CP011 | The TRODELVY HCP support site states the product is supplied as a 180 mg single-dose vial and explicitly offers benefits investigation, prior-authorization support, and assistance for uninsured patients. | 中 | SP010 |
| CP012 | PADCEV competes not only through its label but through formal reimbursement infrastructure: Astellas support materials require payer verification and offer commercial copay assistance up to $25,000 annually. | 高 | SP011, SP012 |
| CP013 | Approved ADC incumbents therefore compete with LigaChem on a full-stack basis that includes label breadth, safety management, reimbursement navigation, and patient-support operations. | 高 | SP006, SP008, SP010, SP012 |
| CP014 | ADC Therapeutics describes itself as a commercial-stage global leader in ADCs and says its portfolio includes an FDA-approved anti-CD19 ADC. | 高 | SP013, SP014 |
| CP015 | ADC Therapeutics' competitive focus remains narrower than large-pharma incumbents because public materials center on ZYNLONTA and hematologic malignancies rather than a multi-tumor commercial platform of ENHERTU scale. | 中 | SP013, SP014, SP024 |
| CP016 | Sutro positions itself as a next-generation ADC platform company with single- and dual-payload capabilities aimed at expanding treatable tumor types and overcoming resistance. | 中 | SP015 |
| CP017 | Sutro's public positioning suggests it competes with LigaChem more on linker-payload and platform sophistication than on current commercial reach. | 中 | SP015, SP021 |
| CP018 | Day One completed the acquisition of Mersana in January 2026, after which Mersana ceased trading on Nasdaq and became a wholly owned subsidiary. | 高 | SP018, SP019 |
| CP019 | Day One bought Mersana for $25 per share in cash plus CVRs, which is adverse evidence that an independent ADC platform can lose standalone bargaining power before late-stage proof is established. | 高 | SP018, SP019 |
| CP020 | Stock Analysis described Mersana before the acquisition as a clinical-stage ADC developer with B7-H4-targeting Emi-Le in phase 1 and additional preclinical assets, showing that technically differentiated platforms still faced financing pressure. | 中 | SP019 |
| CP021 | Hanmi is a credible Korean adjacent challenger because Aju Press reported it showcased BH4601, a B7H3 x PD-L1 bispecific ADC, and several other next-generation oncology modalities at AACR 2026. | 中 | SP026 |
| CP022 | Grand View lists AstraZeneca, Takeda, Roche, ADC Therapeutics, and Seagen among key ADC players, while Research and Markets lists AbbVie, Astellas, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, Roche, and ADC Therapeutics among leading vendors. | 中 | SP022, SP023 |
| CP023 | ChemExpress counted 23 approved ADCs worldwide as of June 30, 2026 across more than ten targets and more than ten tumor types, confirming that the field is no longer a narrow niche. | 中 | SP025 |
| CP024 | ChemExpress identifies Adcetris as a CD30-targeted MMAE ADC with a cleavable valine-citrulline linker and DAR of 4, highlighting how incumbent products already anchor well-understood technical archetypes. | 中 | SP025 |
| CP025 | ChemExpress also argues China-originated programs are increasingly setting the pace in global ADC innovation, adding another source of future partner competition for LigaChem. | 中 | SP025 |
| CP026 | BioMed Nexus says big pharma increasingly views it as faster and safer to buy or partner for ADC assets than to build from scratch, which structurally favors proven commercial buyers over small platform sellers. | 中 | SP024 |
| CP027 | BioMed Nexus and Research and Markets both describe strategic licensing, acquisitions, and vendor crowding as core features of the ADC field, implying high pre-deal multi-homing among pharma buyers. | 中 | SP023, SP024 |
| CP028 | Once a platform partnership is selected, switching costs rise because conjugation chemistry know-how, asset-specific data, and manufacturing process work have to be transferred or rebuilt. | 中 | SP001, SP002, SP024 |
| CP029 | Before deal signature, however, switching costs remain modest because pharma companies can evaluate multiple external ADC platforms and China-originated assets in parallel. | 中 | SP023, SP024, SP025 |
| CP030 | LigaChem lacks public evidence of the downstream reimbursement and patient-support infrastructure visible on approved-franchise sites, reinforcing that its present competition is upstream licensing rather than direct oncology-channel sales. | 高 | SP002, SP006, SP010, SP012 |
| CP031 | The approved-ADC leaders still face material toxicity burdens: ENHERTU warns on interstitial lung disease and neutropenia, ADCETRIS on PML and systemic toxicities, TRODELVY on neutropenia and diarrhea, and PADCEV on skin, lung, and neuropathy risk. | 高 | SP006, SP008, SP009, SP011 |
| CP032 | Manufacturing remains a competitive constraint rather than a solved utility because BioMed Nexus says ADC production combines biologic antibody manufacturing, toxic payload handling, and precise linker conjugation in scarce specialized capacity. | 中 | SP024 |
| CP033 | LigaChem's moat claim is therefore more about conjugation quality, partnerability, and repeat licensing than about being alone in ADC science. | 中 | SP001, SP002, SP022 |
| CP034 | That moat is only partially validated in public evidence because approved-franchise incumbents already own the strongest proof on label breadth, safety management, and reimbursement execution. | 高 | SP005, SP006, SP008, SP010, SP012 |
| CP035 | AbbVie's acquisition of ImmunoGen and Pfizer's takeover of Seagen show that big pharma is willing to pay up for de-risked ADC assets or franchises, which raises the value of strong Ligachem data but also concentrates buyer power in a few global companies. | 中 | SP003, SP016, SP017, SP024 |
| CP036 | Public market profiles for ADCT and STRO show that even known ADC specialists remain small-cap style equities relative to the pharmaceutical incumbents they compete against, a warning signal on standalone platform economics. | 中 | SP003, SP014, SP015, SP020, SP021 |
| CP037 | LigaChem therefore compares best against independent ADC platforms on technology and partnering, but against ENHERTU-, ADCETRIS-, TRODELVY-, and PADCEV-backed incumbents on the standard of proof required to become a preferred licensing counterparty. | 高 | SP002, SP005, SP007, SP009, SP011, SP014, SP015 |
| CP038 | Because 23 ADCs are already approved across many targets, LigaChem cannot rely on modality novelty alone and must differentiate through target choice, linker-payload performance, deal economics, or regional execution speed. | 中 | SP023, SP024, SP025 |
| CI001 | Official 2025 consolidated statements show KRW 141.553 billion of revenue for LigaChem. | 高 | SI001, SI013 |
| CI002 | Official 2025 statements break that revenue into KRW 121.161 billion of licence fee income and KRW 20.392 billion of goods sales. | 中 | SI001 |
| CI003 | Licence fee income accounted for roughly 86% of reported 2025 revenue, making the top line heavily dependent on deal timing rather than recurring product demand. | 中 | SI001 |
| CI004 | The company profile still says LigaChem sells medical device and supplies, which is consistent with goods sales being real but secondary to licensing economics. | 中 | SI001, SI012 |
| CI005 | Official 2025 statements show operating expenses of KRW 248.039 billion, including KRW 216.908 billion of R&D expense and KRW 31.131 billion of selling and administrative expense. | 中 | SI001 |
| CI006 | Official 2025 statements show an operating loss of KRW 106.486 billion. | 高 | SI001, SI013 |
| CI007 | The same official statements imply R&D spending was about 153% of 2025 revenue, underscoring how capital-intensive late-stage development has become. | 中 | SI001 |
| CI008 | Yahoo Finance shows gross profit of roughly KRW 125.996 billion in 2025, implying that reported gross margin looks high because licence fees carry little classical cost of goods sold. | 中 | SI013 |
| CI009 | Operating cash flow was negative KRW 124.533 billion in 2025 on both official and Yahoo cash-flow views. | 高 | SI002, SI014 |
| CI010 | Official cash-flow data show year-end 2025 cash and cash equivalents of KRW 98.650 billion. | 高 | SI002, SI014, SI016 |
| CI011 | Without fresh financing, year-end 2025 cash of KRW 98.650 billion would have covered less than one year of the prior year's operating cash burn. | 高 | SI002, SI014 |
| CI012 | Yahoo's balance-sheet view shows 2025 total assets of KRW 701.815 billion, total liabilities of KRW 160.695 billion, and total equity of KRW 541.120 billion. | 高 | SI003, SI015 |
| CI013 | Yahoo also shows working capital of roughly KRW 460.350 billion and total debt of just KRW 12.644 billion, indicating a lightly levered balance sheet before the 2026 raise. | 中 | SI015 |
| CI014 | Official 2025 cash-flow data show a financing cash inflow of KRW 443.379 billion in 2024, meaning LigaChem had already relied on external capital before the 2026 fundraise. | 高 | SI002, SI014 |
| CI015 | Yahoo's summary page shows Q1 FY26 revenue of KRW 35.89 billion and quarterly earnings of negative KRW 37.33 billion. | 中 | SI011 |
| CI016 | Bizhankook likewise reports first-quarter 2026 revenue of KRW 35.9 billion with sizable quarterly losses, reinforcing that the business remained loss-making entering the 2026 raise. | 中 | SI019 |
| CI017 | The June 2026 recapitalization totaled KRW 500 billion and was structured as KRW 170 billion of convertible bonds plus KRW 330 billion of convertible preferred shares. | 高 | SI008, SI021 |
| CI018 | Official Q&A materials say no discount rate was applied to the 2026 CB/CPS financing. | 中 | SI008 |
| CI019 | WOWTALE says the CB and CPS both have 10-year maturity and conversion rights that become exercisable 24 months after issuance. | 中 | SI021 |
| CI020 | BigGo says the conversion price for both the CB and CPS was KRW 149,300 per share and that full conversion would create about 9.05% additional shares versus the pre-issue base. | 中 | SI022 |
| CI021 | BigGo and Bizhankook both say Pan Orion contributed KRW 125 billion to the 2026 financing, with state-backed or KDB-linked capital supplying KRW 250 billion of the total. | 中 | SI019, SI022 |
| CI022 | Official management comments and WOWTALE say proceeds are earmarked for R&D and late-stage clinical development rather than M&A. | 高 | SI008, SI009, SI021 |
| CI023 | The 2026 raise supports a strategic shift from pure out-licensing toward selective late-stage self-development and eventual commercialization of priority assets. | 高 | SI009, SI021, SI023 |
| CI024 | The Ono package deal disclosed in October 2024 is worth up to $700 million plus royalties, showing how LigaChem monetizes its science through long-duration licensing contracts rather than simple transfer fees. | 中 | SI010 |
| CI025 | Seoul Economic Daily reported that the July 2026 LCB97 milestone payment corresponded to more than 10% of 2025 consolidated revenue, implying a minimum value above KRW 14.1 billion. | 中 | SI020 |
| CI026 | The same Sedaily report says LigaChem issued an invoice the same day and expected payment within 45 days, and that already-received milestone payments are not refundable even if a program later fails. | 中 | SI020 |
| CI027 | Because milestones can produce large revenue spikes but arrive unpredictably, LigaChem's revenue quality is higher on gross margin than on repeatability. | 中 | SI001, SI010, SI020 |
| CI028 | Classic SaaS-style CAC, payback, and sales-efficiency metrics do not fit LigaChem because its main monetization unit is the licensing deal or milestone, not a recurring seat or subscription. | 中 | SI001, SI026 |
| CI029 | A better GTM proxy is deal conversion and milestone progression, but partner-level conversion rates and concentration are not publicly disclosed. | 中 | SI004, SI026 |
| CI030 | Public traction metrics that are actually available include 2025 revenue, 2025 licence fee income, 2025 goods sales, 2025 cash flow, end-2025 cash, and Q1 2026 revenue. | 高 | SI001, SI002, SI011 |
| CI031 | Public metrics that remain missing include partner-by-partner revenue concentration, per-asset R&D spend, realized royalty rates, monthly burn, and exact runway by program. | 中 | SI004, SI006, SI025 |
| CI032 | Bizhankook presents the clearest adverse framing: widening losses, rapidly declining cash assets, and the risk that Orion could be pulled into repeated support as LigaChem takes assets deeper into clinical development. | 中 | SI019 |
| CI033 | Public sources conflict sharply on current cash: Yahoo-based cash-flow views suggest end cash near KRW 60.7 billion for the latest period, while Sedaily cites KRW 418 billion at end-Q1 2026 and Bizhankook cites roughly KRW 450 billion including existing cash before the raise. | 中 | SI014, SI019, SI024 |
| CI034 | That conflict likely reflects differing definitions or cut dates, such as cash and equivalents versus broader liquid resources or pre- versus post-transaction framing, but it prevents a clean public runway model. | 中 | SI014, SI019, SI020, SI021 |
| CI035 | Even using the conservative 2025 burn rate, the KRW 500 billion raise materially extends runway from sub-12 months toward multiple years of gross funding capacity. | 高 | SI002, SI009, SI021 |
| CI036 | However, the same strategy that justifies the raise—more late-stage self-development and commercialization preparation—will likely push burn higher than the simple 2025 base rate. | 中 | SI009, SI019, SI023 |
| CI037 | Yahoo's summary page shows a KRW 4.125 trillion intraday market cap on 2026-08-07, far above current revenue, indicating that equity value is being driven by pipeline expectations rather than earnings power. | 中 | SI011 |
| CI038 | The same page shows an average analyst target around KRW 211,667 versus a market price of KRW 113,200, reinforcing that the stock trades on forward optionality and wide dispersion in expectations. | 中 | SI011 |
| CI039 | The financial verdict from public data is that LigaChem has a credible monetization engine in licensing but not yet a self-sustaining operating model; capital adequacy improved sharply in 2026, while underwriting confidence remains limited by missing program-level and partner-level disclosure. | 中 | SI001, SI002, SI021, SI025 |
| CE001 | LigaChem defines itself as a clinical-stage biopharmaceutical company focused on ADC and immuno-oncology medicines built from medicinal chemistry expertise. | 中 | SE001 |
| CE002 | Official pipeline materials say the company's ADC platform claims differentiation in four specific dimensions: site-specific conjugation, linker stability, efficient toxin release, and pharmacokinetic profile. | 中 | SE002 |
| CE003 | The product delivered to customers is not a single marketed therapy but a stack of ADC assets plus platform-licensing capability that can be paired with external antibodies and partner development engines. | 高 | SE001, SE004, SE010 |
| CE004 | Official ADC pipeline materials enumerate a broad portfolio including HER2-MMAF, ROR1-pPBD, TROP2-MMAE, CD19-pPBD, B7H4-MMAE, L1CAM, CLDN18.2-Topo1i, LRRC15-MMAE, and CD20xCD22-pPBD programs. | 中 | SE003, SE020 |
| CE005 | LCB02A is in a first-in-human Phase 1/2 study for CLDN18.2-positive advanced solid tumors with estimated enrollment of 191 subjects and an estimated start of August 2026. | 中 | SE011 |
| CE006 | The LCB02A trial describes the asset as a CLDN18.2-directed human monoclonal antibody linked to a topoisomerase I inhibiting payload. | 中 | SE011 |
| CE007 | LNCB74 is in a recruiting Phase 1 study for advanced solid tumors with dose-escalation and dose-expansion parts, estimated enrollment of 145, and 21-day IV dosing cycles. | 中 | SE012 |
| CE008 | The LNCB74 trial uses B7-H4 expression assessment by central-lab immunohistochemistry as a named biomarker-related secondary objective. | 中 | SE012 |
| CE009 | IKS014 / LCB14 is in a global recruiting Phase 1 study for HER2-positive and HER2-low solid tumors, including breast and gastric cohorts. | 中 | SE013 |
| CE010 | ClinicalTrials and the NCI Drug Dictionary both describe caxmotabart entudotin / IKS014 / LCB14 as a HER2-targeting ADC with an MMAF payload. | 高 | SE013, SE015 |
| CE011 | The NCI Drug Dictionary adds that caxmotabart entudotin is site-specifically conjugated through a tumor-selective beta-glucuronide linker. | 中 | SE015 |
| CE012 | LCB73 / IKS03 is in a recruiting Phase 1 trial in advanced B-cell non-Hodgkin lymphoma. | 中 | SE014 |
| CE013 | The IKS03 trial describes the payload class as a pyrrolobenzodiazepine pro-drug attached to a CD19-targeting antibody. | 中 | SE014 |
| CE014 | The company's architecture therefore spans multiple payload families—including MMAF, MMAE, pPBD, and Topo1 inhibitor—rather than one linker-payload recipe reused everywhere. | 高 | SE003, SE011, SE013, SE014 |
| CE015 | SOT106 is a LigaChem-platform-derived LRRC15 ADC for sarcomas and other LRRC15-positive malignancies, with global IND submission planned for the second half of 2026. | 高 | SE008, SE009 |
| CE016 | The SOT106 partnership also shows LigaChem often delegates research, development, manufacturing, and commercialization to partners after providing platform technology. | 中 | SE008 |
| CE017 | The Iksuda investment release shows LigaChem sometimes moves beyond arm's-length licensing by taking management stakes to accelerate development and commercialization of transferred assets. | 中 | SE010 |
| CE018 | The same Iksuda release says Caxmotabart Entudotin, LCB73, IKS04, and IKS012 sit inside an integrated transferred pipeline, reinforcing that the platform is modular and partner-portable. | 中 | SE010 |
| CE019 | NextCure's pipeline page independently confirms that LNCB74 is in Phase 1 clinical development and is positioned around improved tumor killing with reduced toxicity. | 高 | SE012, SE024 |
| CE020 | ClinicalTrials locations show that LCB02A, IKS014, and IKS03 are being deployed through international trial networks rather than a Korea-only development model. | 高 | SE011, SE013, SE014 |
| CE021 | The customer or partner workflow runs from target and antibody selection, through ConjuAll-enabled conjugation and preclinical validation, into biomarker-gated clinical trials and, frequently, partner-led commercialization. | 高 | SE002, SE004, SE008, SE011 |
| CE022 | Clinical-trial materials reveal an oncology operating workflow that depends on RECIST response assessment, ECOG status screening, organ-function thresholds, and repeated 21-day IV cycles for at least two lead assets. | 高 | SE011, SE012, SE013 |
| CE023 | LNCB74's trial excludes prior MMAE-ADC exposure, active or historical pneumonitis/ILD requiring steroids, significant neuropathy, and corneal disorders, showing that toxicity management is embedded in protocol design. | 中 | SE012 |
| CE024 | LCB02A's trial excludes prior exposure to ADCs with a Topo1 inhibitor payload, again showing class-specific safety gating at the product-design level. | 中 | SE011 |
| CE025 | IKS014's trial excludes ILD/pneumonitis and clinically significant corneal abnormalities, which are well-known practical risks for certain HER2 ADC regimens. | 中 | SE013 |
| CE026 | Clinical-trial records for the cited lead assets all indicate FDA-regulated drug studies and all state that no expanded access is available. | 高 | SE011, SE012, SE013, SE014 |
| CE027 | No results are posted yet for the cited LCB02A, LNCB74, IKS014, or IKS03 studies, so the public evidence base is still mostly about design, enrollment, and mechanistic rationale rather than efficacy outcomes. | 高 | SE011, SE012, SE013, SE014 |
| CE028 | The careers process page functions as a practitioner proxy because it requires research statements, thesis abstracts, and interview presentations, which is consistent with a scientist-heavy translational R&D organization. | 中 | SE006, SE007 |
| CE029 | Public product-tech evidence does not disclose manufacturing-site certifications, batch-yield metrics, CMC uptime, or released quality-system statistics for the ADC platform. | 中 | SE002, SE004, SE008 |
| CE030 | Frontiers in Oncology and the AACR 2026 review both emphasize that ADC development remains constrained by systemic toxicity, resistance, tumor heterogeneity, and complex manufacturing. | 高 | SE016, SE018 |
| CE031 | AACR 2026 reviews show the broader modality moving toward dual-payload, multi-payload, and bispecific or immune-integrated designs, which raises the bar for a company claiming next-generation ADC leadership. | 高 | SE016, SE017 |
| CE032 | BigGo's roadmap summary says LigaChem is prioritizing LCB02A, LCB36, and LCB58A for accelerated direct development while also securing additional next-generation ADC platforms. | 中 | SE020, SE023 |
| CE033 | Sedaily's June 2026 funding coverage similarly ties the new capital to LCB02A and other proprietary ADC assets entering later-stage or self-development pathways. | 中 | SE021 |
| CE034 | The platform breadth claim is strongest on target and payload variety, but the public depth claim is weaker because most lead programs are still early-phase and efficacy proof remains non-public or partner-authored. | 高 | SE003, SE011, SE012, SE013, SE014 |
| CE035 | The Iksuda release's claim that Caxmotabart Entudotin showed superior efficacy and safety versus Enhertu and Kadcyla in a Chinese partner trial should be treated as company-authored and not as independently verified head-to-head proof. | 中 | SE010 |
| CE036 | The public operating model is therefore hybrid: some assets remain pure partner licenses, while others are being pulled closer to LigaChem through direct development funding or strategic equity stakes. | 高 | SE008, SE010, SE020, SE021 |
| CE037 | Customer workflow at the patient level is biomarker-positive refractory oncology treatment, but customer workflow at the business level is pharma-partner access to conjugation know-how and de-risked pipeline options. | 高 | SE001, SE004, SE011, SE012 |
| CE038 | The core product-tech blockers are missing public manufacturing/quality proof, absent posted clinical results, and dependence on external partners for much of the downstream development and commercialization stack. | 中 | SE008, SE016, SE018, SE025 |
| CU001 | LigaChem's present paying customers are primarily pharma and biotech counterparties that license assets or platform rights, not hospitals or end consumers. | 高 | SU001, SU003, SU005, SU009 |
| CU002 | The practical buyer/user/payer split is partner BD and R&D teams as buyers, partner clinical and commercialization organizations as operators, and milestone or royalty obligations as the economic payment mechanism back to LigaChem. | 高 | SU001, SU005, SU008, SU009 |
| CU003 | LigaChem itself frames the partner model as joint research, co-development, and licensing with global partners. | 中 | SU001 |
| CU004 | The official history page shows repeated partner deal flow from at least Fosun in 2015 through J&J in 2023 and Ono in 2024, which is evidence of sustained business-development adoption rather than a one-off collaboration. | 中 | SU002 |
| CU005 | BigGo reports that LigaChem had signed a total of 15 out-licensing deals through 2024 with cumulative technology export value of about KRW 9.6 trillion by mid-2026. | 中 | SU017 |
| CU006 | The customer base can be segmented into product-license partners, platform-license partners, co-development partners, and rights-split regional partners. | 高 | SU001, SU002, SU006, SU012 |
| CU007 | Ono is both a product customer and a platform customer because the 2024 package deal covered LCB97 rights plus a separate multi-target ConjuAll-based collaboration. | 中 | SU007, SU009 |
| CU008 | Ono received exclusive worldwide rights to develop, manufacture, and commercialize LCB97 for solid tumors, with up to $700 million in upfront and milestone economics plus royalties. | 中 | SU009, SU019 |
| CU009 | The July 2026 Sedaily report shows the Ono relationship has progressed from contract signature into first-patient dosing and a milestone worth more than 10% of LigaChem's prior-year revenue. | 中 | SU019 |
| CU010 | SOTIO is a platform customer that licensed rights for up to five ADC programs and took responsibility for research, development, manufacturing, and commercialization. | 中 | SU008 |
| CU011 | LigaChem's February 2026 SOT106 milestone release confirms the SOTIO relationship remained active several years after signing and was still generating milestone economics. | 中 | SU005, SU008 |
| CU012 | Iksuda is one of the clearest land-and-expand accounts because the relationship spans platform licensing, asset-specific licensing, global clinical advancement, and later strategic equity participation by LigaChem. | 中 | SU006, SU012, SU023 |
| CU013 | The Iksuda-HER2 relationship is geographically split: Iksuda holds global rights to LCB14/IKS014 excluding Greater China and South Korea, while Fosun holds Greater China rights as FS-1502. | 中 | SU012, SU023 |
| CU014 | Iksuda's programs give LigaChem customer proof beyond one molecule because the relationship covers IKS014 / LCB14, IKS03 / LCB73, and additional platform-derived assets such as IKS04 and IKS012. | 中 | SU006, SU012 |
| CU015 | ClinicalTrials records independently confirm that IKS014 and IKS03 are active human studies, which means Iksuda is operating as a real clinical-development customer rather than just a signed logo. | 高 | SU015, SU016 |
| CU016 | CStone is another multi-year customer proof point: it licensed the ROR1 ADC in 2020 and had advanced CS5001 into global Phase 1b by December 2024. | 中 | SU024, SU025 |
| CU017 | CStone's official materials also show the asset is being developed outside Korea under exclusive global rights, reinforcing LigaChem's role as an originator that monetizes via regional or global out-licensing. | 中 | SU024 |
| CU018 | NextCure provides a more modest but still real co-development customer surface because its pipeline page confirms LNCB74 is in Phase 1 clinical development. | 高 | SU010, SU014 |
| CU019 | Janssen / Johnson & Johnson is a named big-pharma product customer for LCB84, with a deal value of up to $1.7 billion and a collaboration during the ongoing Phase 1/2 trial before Janssen assumes sole downstream responsibility. | 中 | SU011, SU002 |
| CU020 | The retained customer set is geographically diverse across Japan, China, the United Kingdom, continental Europe, and the United States, which reduces dependence on a single domestic BD channel. | 高 | SU002, SU009, SU012, SU024 |
| CU021 | Adoption proof is strongest when a relationship has crossed at least one hard boundary such as IND approval, first-patient dosing, milestone receipt, or clinical-trial enrollment. | 高 | SU005, SU015, SU019, SU024 |
| CU022 | Several named customer relationships have crossed those hard boundaries: Ono to first-patient milestone, SOTIO to milestone plus pre-IND progress, Iksuda to first-patient and Phase 1 activity, and CStone to Phase 1b expansion. | 中 | SU005, SU019, SU023, SU024 |
| CU023 | LigaChem's customer journey runs from target or platform fit, through licensing and rights allocation, into partner-led clinical execution and eventually milestone or royalty flows. | 高 | SU001, SU008, SU009, SU012 |
| CU024 | Many customers—notably Ono and SOTIO—control downstream development, manufacturing, and commercialization rights, which means LigaChem often gives up operational control after creating or transferring the asset. | 中 | SU008, SU009 |
| CU025 | That structure makes customer monetization inherently lumpy: economics are driven by deal signing, option exercise, first-patient dosing, regulatory milestones, and eventual royalties rather than monthly recurring usage. | 中 | SU005, SU009, SU019 |
| CU026 | There is no public disclosure in retained sources for customer count by cohort, renewal rate, GRR, NRR, or revenue concentration by named partner. | 中 | SU017, SU019, SU020, SU021 |
| CU027 | In lieu of SaaS-style retention metrics, the best public proxy for durability is multi-year continuity from initial deal to later trials, options, milestones, or expanded rights. | 高 | SU002, SU005, SU006, SU024 |
| CU028 | Iksuda, SOTIO, CStone, and Ono all show explicit multi-year continuity between original deal announcement and later operational proof, which supports a favorable durability proxy even though renewal metrics are absent. | 中 | SU005, SU006, SU009, SU024 |
| CU029 | The customer-quality hierarchy is strongest for Ono, Iksuda, SOTIO, and CStone because those relationships have both named official proof and later-stage operational proof. | 中 | SU005, SU009, SU023, SU024 |
| CU030 | NextCure and Janssen are still credible named accounts, but their public proof retained here is thinner on recent milestones than the Ono, Iksuda, SOTIO, or CStone relationships. | 中 | SU010, SU011 |
| CU031 | Public evidence does not provide meaningful partner-side satisfaction data or any disclosed dissatisfaction metrics; customer satisfaction must therefore be treated as unverified. | 中 | SU001, SU005, SU009 |
| CU032 | The 2026 financing narrative shows the company is trying to keep the licensing-out customer model while adding a self-development option for selected priority assets. | 中 | SU017, SU018, SU020 |
| CU033 | That shift does not erase the customer base; instead it changes LigaChem's posture from pure technology seller toward a hybrid that can choose between earlier monetization and deeper value capture. | 中 | SU006, SU017, SU020 |
| CU034 | Customer concentration risk is probably material because a handful of milestone-bearing partners appear to account for most publicly visible commercial proof and because the company does not disclose partner-level revenue splits. | 中 | SU019, SU021 |
| CU035 | The Bizhankook article reinforces the concentration and durability concern indirectly by stressing that larger self-development commitments can raise dependence on a limited set of counterparties and capital providers before broad royalty flows exist. | 中 | SU021 |
| CU036 | The strategic value of anchor customers is high because they validate both asset-specific programs and the broader ConjuAll platform in negotiations with future global pharma partners. | 中 | SU005, SU009, SU011 |
| CU037 | New-partner adoption friction is likely nontrivial because counterparties need rights negotiation, target selection, payload-linker fit, and a long clinical-development commitment before commercialization is visible. | 高 | SU001, SU008, SU012 |
| CR001 | The public disclosure page shows that LigaChem remains highly event-driven, with material management information and voluntary disclosures tied to financing events, milestones, and rights changes. | 中 | SR001 |
| CR002 | The lead ADC portfolio is still predominantly early-phase or pre-IND, so clinical failure remains the first-order risk for the equity story. | 高 | SR014, SR015, SR016, SR017, SR029 |
| CR003 | None of the cited ClinicalTrials studies for LCB02A, LNCB74, IKS014, or IKS03 had posted results in the retained evidence set. | 高 | SR014, SR015, SR016, SR017 |
| CR004 | LNCB74 excludes prior MMAE-ADC exposure, ILD/pneumonitis, neuropathy, and corneal disorders, which is concrete evidence that toxicity window remains a live development risk. | 中 | SR015 |
| CR005 | LCB02A excludes prior Topo1-payload ADC exposure, showing that payload-class toxicity and prior-treatment history are active regulatory design constraints. | 中 | SR014 |
| CR006 | IKS014 excludes ILD/pneumonitis and clinically significant corneal abnormalities, again reinforcing that payload-associated pulmonary and ocular risks matter in real-world development. | 中 | SR016 |
| CR007 | Frontiers summarizes the generic ADC risk stack as systemic toxicity, drug resistance, tumor heterogeneity, and complex manufacturing. | 中 | SR018 |
| CR008 | AACR 2026 reviews show the competitive bar is moving toward bispecific and multi-payload ADCs, creating technology-obsolescence risk for any platform that cannot keep pace. | 高 | SR019, SR020 |
| CR009 | ClinicalTrials entries show enrollment targets of 191 for LCB02A, 145 for LNCB74, 165 for IKS014, and 140 for IKS03, implying substantial recruitment and execution burden across several concurrent studies. | 高 | SR014, SR015, SR016, SR017 |
| CR010 | Because the company now appears to be juggling multiple internal and partnered programs at once, portfolio-sprawl risk is rising rather than falling. | 中 | SR004, SR009, SR011 |
| CR011 | The 2024 package deal with Ono transferred exclusive worldwide development, manufacturing, and commercialization rights for LCB97 while also granting broader platform access, which makes LigaChem dependent on a partner for downstream execution. | 高 | SR025, SR012 |
| CR012 | SOTIO similarly controls research, development, manufacturing, and commercialization for the licensed ADC products under its agreement, leaving LigaChem reliant on partner follow-through. | 高 | SR024, SR029 |
| CR013 | The Iksuda structure adds complexity because LigaChem is simultaneously a licensor, strategic investor, and potential controlling shareholder in a counterparty that runs key pipeline programs. | 中 | SR028, SR031 |
| CR014 | CStone and NextCure provide validation but also confirm that major parts of the platform outcome are mediated by external clinical operators rather than by LigaChem alone. | 中 | SR026, SR027, SR030 |
| CR015 | The customer and partner model diversifies scientific validation but concentrates economic timing, because milestone events are tied to a finite number of counterparties and assets. | 中 | SR012, SR029, SR032 |
| CR016 | Ono's July 2026 milestone appears to be worth at least 10% of 2025 consolidated revenue, which is strong validation but also evidence that a single customer event can be financially material. | 中 | SR012 |
| CR017 | No retained public source discloses partner-level revenue concentration, churn, renewal behavior, or royalty timing. | 中 | SR009, SR010, SR011, SR012 |
| CR018 | Official 2025 statements show KRW 141.6 billion of revenue but KRW 248.0 billion of operating expenses and KRW 106.5 billion of operating loss, confirming that the pre-2026 model was not self-funding. | 中 | SR007 |
| CR019 | Official 2025 cash-flow statements show KRW 124.5 billion of operating cash outflow and only KRW 98.7 billion of year-end cash, which implies substantial funding risk absent the 2026 recapitalization. | 中 | SR008 |
| CR020 | The 2026 KRW 500 billion raise materially reduces near-term runway risk, but independent coverage makes clear that the company intends to spend that capital on late-stage clinical development, regulatory approval, manufacturing, and commercialization. | 中 | SR009, SR011, SR013 |
| CR021 | That spending plan means the raise solves timing risk more than it solves structural capital-intensity risk. | 中 | SR009, SR011, SR013 |
| CR022 | BigGo reports roughly 9.05% fully diluted share issuance from the CB/CPS package, showing that financing relief came with meaningful dilution potential. | 中 | SR009 |
| CR023 | Bizhankook argues that late-stage self-development, rising outsourcing cost, and widened losses can reopen questions about future Orion support despite the 2026 raise. | 中 | SR010 |
| CR024 | The public shift toward self-development therefore increases total execution complexity: LigaChem is trying to retain the upside of deeper control without yet having a marketed-product operating history. | 中 | SR011, SR013, SR025 |
| CR025 | Google Patents records show active LigaChem-assigned patents covering self-immolative groups and related conjugates, which is a real mitigation against pure platform commoditization. | 高 | SR021, SR022 |
| CR026 | Those same sources do not provide a complete freedom-to-operate map, litigation history for LigaChem's own families, or a portfolio-wide expiry schedule, so legal/IP uncertainty remains material. | 中 | SR021, SR022, SR004 |
| CR027 | The broader ADC IP field can be contentious: the comparator site-specific conjugation patent family cited here is marked as having litigation, showing that relevant patent estates can become contested. | 中 | SR023 |
| CR028 | Official history pages mention ConjuAll patent registrations in the U.S. and Japan plus novel linker chemistry patents, but public disclosures stop well short of a diligence-grade IP landscape. | 中 | SR004, SR021, SR022 |
| CR029 | The disclosure page itself is thin and list-like, which helps compliance but does not meaningfully reduce information asymmetry about the details of material events. | 中 | SR001 |
| CR030 | The governance page shows Orion-linked directors on the board, which improves sponsor alignment but also increases related-party and strategic-control sensitivity. | 中 | SR002 |
| CR031 | The leadership page shows named senior coverage for ADC research, toxicology/safety, and manufacturing/CMC, which partially mitigates execution risk by indicating that these functions are explicitly recognized. | 中 | SR003 |
| CR032 | The careers process page suggests LigaChem depends on highly specialized scientific talent, which means scaling delays or turnover in translational chemistry and clinical-development functions could be costly. | 中 | SR005 |
| CR033 | Because the company still lacks a marketed product, commercial-execution risk remains largely untested even if the science continues to progress. | 中 | SR011, SR025 |
| CR034 | SOT106, LCB97, CS5001, IKS014, IKS03, and LNCB74 all provide proof of partner appetite, but they also create many external handoff points where timing can slip outside LigaChem's control. | 中 | SR024, SR025, SR027, SR028, SR029, SR030 |
| CR035 | The rights-split around LCB14 / IKS014 / FS-1502 introduces additional coordination risk because one asset family is being advanced by different counterparties across territories. | 中 | SR031, SR016, SR022 |
| CR036 | NextCure's public description of LNCB74 as designed to reduce toxicity is directionally positive, but it does not substitute for disclosed human outcome data, so downside risk remains only partially mitigated. | 中 | SR026, SR015 |
| CR037 | CStone's official Phase 1b progression for CS5001 shows that some partnered assets are advancing well, but it also highlights that value realization depends on external companies choosing to keep investing through later stages. | 中 | SR027, SR030 |
| CR038 | The 2026 disclosure headline referencing sole-development rights and technology-transfer rights for LNCB74 shows that counterparty and rights architecture can still change materially, which is both optionality and governance risk. | 中 | SR001 |
| CR039 | No retained public source discloses named GMP certifications, batch-failure rates, release metrics, or recurrent supply-quality indicators for the ADC platform. | 中 | SR003, SR018 |
| CR040 | ADC reviews and protocol constraints together imply that even successful trial progression would leave residual exposure to manufacturing complexity, safety window management, and competitive benchmark risk. | 高 | SR014, SR015, SR018, SR019 |
| CR041 | The cleanest thesis-break triggers through 2027 would be: a major safety setback in LCB02A or LNCB74, a delayed IND or Phase 1 start for roadmap assets like LCB36/LCB58A, or evidence that the 2026 war chest is being consumed faster than milestones refill it. | 中 | SR009, SR010, SR011, SR014, SR015 |
| CR042 | The main diligence asks are therefore partner-level economics, full IP/FTO mapping, CMC quality evidence, and updated trial readouts; without those, residual risk stays high even if the narrative remains strong. | 中 | SR017, SR018, SR021, SR022 |
| CV001 | Yahoo Finance places LigaChem at a share price of KRW 113,200 and an intraday market cap of roughly KRW 4.125 trillion on 2026-08-07. | 中 | SV004 |
| CV002 | Yahoo analyst data shows current-year 2026 sales estimates of roughly KRW 284 billion and 2027 estimates of roughly KRW 286.48 billion. | 中 | SV005 |
| CV003 | At the current market cap, LigaChem is trading at roughly 14.5x 2026 estimated sales and about 14.4x 2027 estimated sales. | 中 | SV004, SV005 |
| CV004 | Yahoo shows a one-year analyst target estimate of roughly KRW 211,667 with a high target around KRW 230,000, implying visible modeled upside from the current quote. | 中 | SV004 |
| CV005 | That analyst-upside signal should be treated cautiously because the coverage base is thin and the business remains event-driven and clinical-stage. | 中 | SV004, SV005, SV001 |
| CV006 | Official financial statements confirm that 2025 revenue was KRW 141.6 billion and operating cash outflow was KRW 124.5 billion, so the equity story is still pricing future optionality rather than mature cash generation. | 高 | SV002, SV003 |
| CV007 | The 2026 KRW 500 billion raise materially improved runway and helps support a premium versus weaker cash-strapped clinical biotechs. | 中 | SV006, SV007, SV009 |
| CV008 | The same raise also confirms that LigaChem is moving into a more capital-intensive phase, which means part of the premium is being spent to buy strategic optionality rather than current earnings power. | 中 | SV007, SV008, SV009 |
| CV009 | BigGo reports that LigaChem had signed 15 out-licensing deals through 2024 with cumulative technology-export value of about KRW 9.6 trillion, which supports the argument for strategic platform value. | 中 | SV006 |
| CV010 | Ono, SOTIO, Janssen, Iksuda, NextCure, and CStone together provide a stronger customer-validation surface than most clinical-stage biotech peers enjoy. | 高 | SV010, SV011, SV013, SV029, SV030 |
| CV011 | However, there is still no marketed flagship LigaChem-owned product and no posted results for the current lead-trial set cited in this report. | 高 | SV014, SV015, SV016, SV017 |
| CV012 | That combination—real partner validation but incomplete human proof—means the company should be valued more as an option-rich platform than as a de-risked commercial oncology franchise. | 高 | SV006, SV010, SV014, SV015 |
| CV013 | ADC Therapeutics currently trades at about $146 million market cap on Yahoo Finance and about $140 million on CompaniesMarketCap, despite being a public ADC company with commercial exposure. | 中 | SV022, SV023 |
| CV014 | Sutro Biopharma currently trades at about $408 million market cap on Yahoo Finance and about $400 million on CompaniesMarketCap. | 中 | SV024, SV025 |
| CV015 | CStone Pharmaceuticals shows a market cap of about HKD 6.89-8.38 billion on Yahoo Finance, which is roughly sub-$1 billion USD and still well below LigaChem’s current public value. | 高 | SV026, SV013 |
| CV016 | These public-biotech comparables imply that LigaChem currently trades at a substantial premium to listed ADC or oncology-development peers on absolute market cap. | 中 | SV004, SV022, SV023, SV024, SV025, SV026 |
| CV017 | The premium is not irrational: LigaChem has broader platform optionality, meaningful licensing economics, and stronger strategic validation than many small public peers. | 中 | SV006, SV010, SV011, SV029, SV030 |
| CV018 | But the premium is still difficult to defend fully when current-trial proof is early and product revenue is not yet established. | 高 | SV002, SV014, SV015, SV016, SV017 |
| CV019 | Pfizer paid about $43 billion enterprise value for Seagen, a world-leading ADC franchise with approved products, scale, and deep pipeline breadth. | 高 | SV027, SV018 |
| CV020 | AbbVie paid $31.26 per share for ImmunoGen after ELAHERE approval, with the press release emphasizing approved-product status, label-expansion potential, and late-stage ADC pipeline value. | 高 | SV028, SV018 |
| CV021 | Those strategic M&A anchors show how much value the market can ascribe to differentiated ADC assets once product approval and commercialization are visible. | 高 | SV019, SV020 |
| CV022 | LigaChem is not yet close enough to those de-risked strategic precedents to justify being valued on the same logic today. | 高 | SV004, SV027, SV028 |
| CV023 | The company therefore sits awkwardly between two comp families: richer than current public clinical-stage ADC peers, but materially less de-risked than approved-product strategic takeouts. | 高 | SV016, SV019, SV022, SV024, SV027, SV028 |
| CV024 | A mixed comparable framework—public peers, strategic M&A, and deal-level licensing references—is more defensible than a single-multiple approach. | 高 | SV006, SV023, SV025, SV027, SV028, SV030 |
| CV025 | The Ono package deal, SOTIO multi-target agreement, and Janssen LCB84 deal all show that asset-level or program-level value creation can be large even before commercialization. | 高 | SV010, SV011, SV030 |
| CV026 | However, theoretical milestone ceilings cannot be capitalized at par because they depend on development success, counterparty persistence, timing, and downstream approvals. | 中 | SV010, SV011, SV030, SV008 |
| CV027 | Current public filings and disclosures show that LNCB74 and LCB97-related events are still material enough to move the information surface, which reinforces the event-driven nature of the stock. | 高 | SV001, SV004 |
| CV028 | The core thesis is that LigaChem owns real ADC option value across several assets and partnerships. | 高 | SV006, SV010, SV011, SV020, SV021 |
| CV029 | The core anti-thesis is that much of that option value is already reflected in the public market cap before current human-readout and CMC questions are answered. | 高 | SV003, SV004, SV005, SV011, SV018 |
| CV030 | At today’s quote, the correct recommendation is not buy but track / research more. | 高 | SV003, SV004, SV005, SV008, SV018 |
| CV031 | Confidence should be medium because valuation support exists, but comp fit and core proof remain imperfect. | 中 | SV004, SV005, SV023, SV027, SV028 |
| CV032 | Risk rating should remain high because the company is still clinical-stage, burn-heavy, and dependent on partner execution plus future data. | 高 | SV003, SV008, SV014, SV015 |
| CV033 | Valuation stance is rich but not absurd: the company deserves a premium to weaker ADC peers, yet current pricing still requires either more proof or better entry discipline. | 高 | SV004, SV006, SV022, SV024, SV028 |
| CV034 | The bull case requires at least three things to go right at once: strong early human data in self-advanced assets, continued partner milestone conversion, and evidence that self-development expands value faster than it increases burn. | 中 | SV006, SV007, SV010, SV014, SV015 |
| CV035 | The base case assumes the platform stays strategically relevant and financially viable, but that value accrues more slowly than the current premium might imply. | 中 | SV003, SV006, SV010, SV011, SV018 |
| CV036 | The bear case combines clinical delay, heavier-than-expected burn, partner slippage, and multiple compression toward public-peer territory. | 中 | SV003, SV008, SV022, SV024 |
| CV037 | A price compression toward roughly KRW 2.0-2.5 trillion equivalent, if unaccompanied by thesis damage, would make the entry case materially more interesting for new capital. | 中 | SV004, SV022, SV024 |
| CV038 | Conversely, a higher price without human-readout or CMC de-risking would worsen the risk/reward balance. | 中 | SV004, SV014, SV015, SV018 |
| CV039 | The most valuation-sensitive unknowns are LCB02A human data, partner milestone cadence, future dilution needs, and CMC proof. | 高 | SV003, SV006, SV014, SV015, SV020 |
| CV040 | Final diligence should focus on partner-level economics, runway to key readouts, CMC readiness, and freedom-to-operate, because those four areas would move both scenario probabilities and comp selection. | 高 | SV003, SV020, SV021, SV030 |
| CV041 | Exit-readiness is only medium-low today: the company is already public, but there is no visible approved-product or M&A process that would justify using a near-term exit multiple as a primary anchor. | 中 | SV004, SV027, SV028 |
| CV042 | The most important thesis-break triggers through 2027 are: safety or efficacy disappointment in lead assets, evidence the 2026 cash war chest is insufficient, or partner momentum slowing rather than compounding. | 中 | SV003, SV008, SV014, SV015 |
| 编号 | 出版方 | 标题 | 引文 |
|---|---|---|---|
| SO001 | LigaChem Biosciences | LigaChem Biosciences homepage | |
| SO002 | LigaChem Biosciences | About Us - Overview | LCB is a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative medicines. |
| SO003 | LigaChem Biosciences | History | |
| SO004 | LigaChem Biosciences | Leadership | |
| SO005 | LigaChem Biosciences | Message from Chairman | Since founding LigaChem Biosciences in 2006, I have been striving my utmost to realize the lifelong mission to this day. |
| SO006 | LigaChem Biosciences | Location | |
| SO007 | LigaChem Biosciences | VISION 2030 | |
| SO008 | LigaChem Biosciences | Partnerships | |
| SO009 | LigaChem Biosciences | Stock | |
| SO010 | LigaChem Biosciences | Disclosure | |
| SO011 | LigaChem Biosciences | Governance | |
| SO012 | LigaChem Biosciences | Shareholder notice on National Growth Fund direct investment | The company has attracted direct equity investment of 500 billion won from the National Growth Fund. |
| SO013 | LigaChem Biosciences | Investor Q&A on National Growth Fund direct investment | This funding consists of 170 billion won in CB and 330 billion won in CPS, and no discount rate was applied. |
| SO014 | LigaChem Biosciences | Press release to shareholders on National Growth Fund direct investment | |
| SO015 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Company Profile & Facts | |
| SO016 | Stock Analysis / S&P Global Market Intelligence | LigaChem Biosciences (KOSDAQ:141080) Company Profile & Description | |
| SO017 | Financial Supervisory Service DART | LigaChem Biosciences / Notice on Investor Relations / 2026.06.30 | |
| SO018 | Korea Biomedical Review | Korea's chip fund makes first biotech bet, backing LigaChem with $323 million | |
| SO019 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund in First Direct Investment in Biotech Sector | |
| SO020 | The Korea Economic Daily / Seoul Economic Daily English | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SO021 | NEWSTOP | LigaChem Biosciences Secures $323.6 Million From National Growth Fund | However, this favorable mood is not directly affecting the share prices of listed biotech companies in today's trading. |
| SO022 | BioSpace | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million and an option exercise payment of USD 200 million. |
| SO023 | Pharmaceutical Technology | J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem | |
| SO024 | CHOSUNBIZ | Public Growth Fund backs LigaChem and approves LIG D&A investment in Korea | |
| SO025 | thebell | 리가켐바이오, 국민성장펀드 "5000억 유치" 신약사 첫 사례 | |
| SM001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SM002 | LigaChem Biosciences | Partnerships | |
| SM003 | LigaChem Biosciences | VISION 2030 | |
| SM004 | Grand View Research | Antibody Drug Conjugates Market Size | Industry Report 2030 | The global antibody drug conjugates market size was estimated at USD 11.29 billion in 2023 and is expected to reach USD 24.01 billion by 2030. |
| SM005 | The Business Research Company | Antibody Drug Conjugates Market Size, Drivers Report 2026-2030 | The antibody drug conjugates market size will grow from $16.53 billion in 2025 to $20.28 billion in 2026. |
| SM006 | Research and Markets | Antibody Drug Conjugates Market 2026-2030 | The global antibody drug conjugates market is forecasted to grow by USD 13.77 billion during 2025-2030, accelerating at a CAGR of 15.7%. |
| SM007 | Mordor Intelligence | Antibody Drug Conjugates Market Size, Share & Industry Growth Report 2031 | The Antibody Drug Conjugates Market size is expected to grow from USD 15.61 billion in 2025 to USD 20.12 billion in 2026 and is forecast to reach USD 71.55 billion by 2031. |
| SM008 | Fairfield Market Research | Antibody Drug Conjugate Market Size, Growth and Outlook 2033 | The global antibody drug conjugate market is expected to be valued at US$ 16.80 Billion in 2026 and is projected to reach US$ 35.99 Billion by 2033. |
| SM009 | U.S. Food and Drug Administration | Novel Drug Approvals for 2026 | |
| SM010 | U.S. Food and Drug Administration | Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry | |
| SM011 | Experimental Hematology & Oncology / Springer | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SM012 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SM013 | ADC Review | AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1) | |
| SM014 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SM015 | Roche | Product Development Pipeline | |
| SM016 | Roche | Roche to present new data at ASCO 2026 | |
| SM017 | NICE | NICE publishes final draft guidance on Enhertu after commercial discussions conclude | Without a commercial arrangement that results in a price that represents a cost-effective use of NHS resources, NICE cannot recommend Enhertu. |
| SM018 | NICE | Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | |
| SM019 | Astellas Pharma Support Solutions | PADCEV Support Solutions for Healthcare Providers | |
| SM020 | NICE | Technology appraisal data: cancer appraisal recommendations | |
| SM021 | NICE | Economic evaluation | NICE technology appraisal manual | |
| SM022 | Pfizer CentreOne | ADC Services | Antibody Drug Conjugates | |
| SM023 | Bristol Myers Squibb | Science in action | |
| SM024 | LigaChem Biosciences | History | |
| SM025 | ICER | Policy Papers | Explore Our Research | |
| SP001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SP002 | LigaChem Biosciences | Partnerships | |
| SP003 | Pfizer | Investor Relations Overview | |
| SP004 | Daiichi Sankyo | Shareholders & Investors | |
| SP005 | ENHERTU | Official Patient Website | ENHERTU is a prescription medicine used to treat adults with ... HER2-positive ... HER2-low ... HER2-ultralow ... NSCLC ... gastric cancer ... solid tumors. |
| SP006 | ENHERTU | Official HCP Site | ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for ... HER2-Positive Early Breast Cancer ... HER2-Positive Metastatic Breast Cancer ... HER2-Low and HER2-Ultralow ... NSCLC ... Gastric Cancer ... Solid Tumors. |
| SP007 | ADCETRIS | Official Patient Website | ADCETRIS is FDA approved to treat certain types of lymphoma across 8 different indications. |
| SP008 | ADCETRIS | Official HCP Website | JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients. |
| SP009 | TRODELVY | Official Patient Website | TRODELVY can cause serious side effects, including low white blood cell count and diarrhea. |
| SP010 | TRODELVY | Financial Assistance & Cost Support for HCPs | TRODELVY (180 mg) for injection is supplied as a sterile ... single-dose vial. |
| SP011 | PADCEV | Official Patient Site | PADCEV may cause serious side effects, including: Skin reactions ... Lung problems ... Nerve problems. |
| SP012 | Astellas Pharma Support Solutions | PADCEV Support Solutions for Healthcare Providers | The Program has an annual maximum copay assistance limit of $25,000 per calendar year. |
| SP013 | ADC Therapeutics | Corporate Website | Our technology includes an FDA-approved anti-CD19 ADC. |
| SP014 | ADC Therapeutics | Investors | Overview | ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). |
| SP015 | Sutro Biopharma | Investors | At Sutro, we are advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs. |
| SP016 | AbbVie | Investor Overview | |
| SP017 | AbbVie | AbbVie Completes Acquisition of ImmunoGen | |
| SP018 | Day One Biopharmaceuticals | Day One Completes Acquisition of Mersana Therapeutics | Mersana became a direct wholly owned subsidiary of Day One. |
| SP019 | Stock Analysis | Mersana Therapeutics (MRSN) Company Profile & Description | Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN). |
| SP020 | Yahoo Finance | ADC Therapeutics SA (ADCT) Company Profile & Facts | |
| SP021 | Yahoo Finance | Sutro Biopharma, Inc. (STRO) Company Profile & Facts | |
| SP022 | Grand View Research | Antibody Drug Conjugates Market Size | Industry Report 2030 | Key players, such as AstraZeneca, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., ADC Therapeutics, Seagen, Inc., and others, are collaborating to develop & commercialize these products. |
| SP023 | Research and Markets | Antibody Drug Conjugates Market 2026-2030 | The report provides a detailed analysis of several leading global antibody drug conjugates market vendors. |
| SP024 | BioMed Nexus | ADCs in 2026: The Deals, the Data and the Players | Enhertu ... has become the best-selling ADC ... Pfizer’s acquisition of Seagen, valued at roughly $43 billion, was the defining ADC deal. |
| SP025 | ChemExpress | Global ADC Landscape 2026H1 | As of June 30, 2026, 23 antibody-drug conjugates (ADCs) have received regulatory approval worldwide. |
| SP026 | Aju Press | Hanmi Pharmaceutical Unveils Next-Generation Cancer Drug Pipeline at AACR 2026 | Hanmi said BH4601 is a bispecific antibody-drug conjugate that targets B7H3 and PD-L1 at the same time. |
| SI001 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (income statement view) | Revenue 141,553 ... Licence fee income 121,161 ... Operating profit -106,486. |
| SI002 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (cash flow view) | Cash flows from operating activities -124,533 ... Cash and cash equivalents at the end of period 98,650. |
| SI003 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (balance sheet view) | Total Assets 701,815 ... Total Liabilities 160,694 ... Total Equity 541,120. |
| SI004 | LigaChem Biosciences | Disclosure | Results of issuance (Voluntary Disclosure) ... [Revised] Decision on Paid-in Capital Increase ... [Revised] Decision on Issuance of Convertible Bonds ... LCB97 milestone technology fee receipt. |
| SI005 | LigaChem Biosciences | Stock | |
| SI006 | LigaChem Biosciences | Notice: Consolidated Financial Statements 2025 | |
| SI007 | LigaChem Biosciences | Shareholder notice on National Growth Fund direct investment | |
| SI008 | LigaChem Biosciences | Investor Q&A on National Growth Fund direct investment | This funding consists of 170 billion won in CB and 330 billion won in CPS, and no discount rate was applied. |
| SI009 | LigaChem Biosciences | Press release to shareholders on National Growth Fund direct investment | |
| SI010 | LigaChem Biosciences | Press release: two ADC technology transfer deals with Ono Pharmaceutical | Ono Pharmaceutical will pay up to $700 million in upfront, development, and sales milestones, with royalties after commercialization. |
| SI011 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Summary | Market Cap (intraday) 4.125T ... Q1 FY26 Revenue 35.89B Earnings -37.33B. |
| SI012 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Company Profile & Facts | It also sells medical device and supplies. |
| SI013 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Income Statement | Gross Profit 125,995,662.56 ... Operating Income -106,485,861.44. |
| SI014 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Cash Flow | Operating Cash Flow -124,532,936.67 ... End Cash Position 98,649,999.02. |
| SI015 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Balance Sheet | Working Capital 460,349,830.55 ... Total Debt 12,643,935.24. |
| SI016 | Investing.com | LigaChem Biosciences (141080) Balance Sheet | Cash and Equivalents ... 98,650. |
| SI017 | Investing.com | LigaChem Biosciences Inc (141080) Cash Flow | Cash from Operations ... -124,532.94 ... Cash from Investing ... 94,141.31. |
| SI018 | Stockopedia | LigaChem Biosciences Income Statement (Aug 2026) | |
| SI019 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | With losses widening and cash assets declining rapidly, LigaChem Biosciences is facing significant cash burn. |
| SI020 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | The exact amount is confidential ... but it corresponds to more than 10% of the company's consolidated revenue of 141.55307 billion won last year. |
| SI021 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | The investment is structured as KRW 170 billion in convertible bonds and KRW 330 billion in convertible preferred shares, both with a 10-year maturity. |
| SI022 | BigGo Finance | South Korea's National Growth Fund Makes First Direct Investment in Biotech, Backing LigaChem Bio | The conversion price for both the CB and CPS is set at 149,300 won per share. |
| SI023 | Seedtable | LigaChem Biosciences Raises 323.0M USD in Growth Funding | The capital ... funds a strategic shift from pure out-licensing toward taking priority assets through late-stage trials and commercialization in-house. |
| SI024 | CHOSUNBIZ | Public Growth Fund backs LigaChem and approves LIG D&A investment in Korea | |
| SI025 | LigaChem Biosciences | About Us - Overview | |
| SI026 | LigaChem Biosciences | Partnerships | |
| SE001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SE002 | LigaChem Biosciences | Pipeline | Site-Specific Conjugation, Linker Stability, Efficient Toxin Release, PK profile. |
| SE003 | LigaChem Biosciences | ADC Pipeline | |
| SE004 | LigaChem Biosciences | Partnerships | |
| SE005 | LigaChem Biosciences | History | |
| SE006 | LigaChem Biosciences | Careers - Process | Required Documents: ... research statement ... Thesis abstract ... Recommendation letter from the academic advisor (preferred). |
| SE007 | LigaChem Biosciences | Careers - Our Culture | |
| SE008 | LigaChem Biosciences | Press release: SOT106 milestone and 2026 IND plan | SOT106 ... developed using LigaChem's ADC platform ... SOTIO intends to submit global IND application for SOT106 in the second half of 2026. |
| SE009 | LigaChem Biosciences | Press release: SOTIO milestone (Korean) | |
| SE010 | LigaChem Biosciences | Press release: strategic investment in Iksuda | IKSUDA currently possesses several promising oncology pipelines through multiple substance and platform technology transfers from LigaChem Bio. |
| SE011 | ClinicalTrials.gov API | NCT07460375 - LCB02A | LCB02A ... CLDN18.2-directed human monoclonal antibody linked to a topoisomerase I inhibiting payload. |
| SE012 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | LNCB74 is an antibody drug conjugate ... IV in 21-day dosing cycles. |
| SE013 | ClinicalTrials.gov API | NCT05872295 - IKS014 | IKS014 is a human monoclonal antibody targeting HER2 linked to monomethyl auristatin F (MMAF). |
| SE014 | ClinicalTrials.gov API | NCT05365659 - IKS03 | IKS03 is a human monoclonal antibody targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug. |
| SE015 | National Cancer Institute | NCI Drug Dictionary - caxmotabart entudotin | site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to ... MMAF. |
| SE016 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SE017 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SE018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SE019 | ChemExpress | Global ADC Landscape 2026H1 | |
| SE020 | BigGo Finance | South Korea's National Growth Fund Makes First Direct Investment in Biotech, Backing LigaChem Bio | The company has identified three core pipeline programs for accelerated direct development. |
| SE021 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SE022 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SE023 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SE024 | NextCure | Pipeline | LNCB74 has been specifically designed to reduce toxicity while improving tumor killing. |
| SE025 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SU001 | LigaChem Biosciences | Partnerships | Accelerating global new drug development through joint research, co-development, and licensing with global partners. |
| SU002 | LigaChem Biosciences | History | |
| SU003 | LigaChem Biosciences | About Us - Overview | |
| SU004 | LigaChem Biosciences | ADC Pipeline | |
| SU005 | LigaChem Biosciences | Press release: SOT106 milestone and 2026 IND plan | LCB is eligible to receive upfront and potential milestone payments worth up to $1027.5 million ... plus royalties on net sales. |
| SU006 | LigaChem Biosciences | Press release: Iksuda strategic investment and pipeline expansion | |
| SU007 | LigaChem Biosciences | Press release: Ono package deal for LCB97 and ConjuAll platform | |
| SU008 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products. |
| SU009 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97 for solid tumors. |
| SU010 | NextCure | Pipeline | LNCB74 is currently in Phase 1 clinical development. |
| SU011 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | LCB is eligible for up to potentially USD 1.7 billion in total consideration. |
| SU012 | Web Archive / Business Wire | Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 ADC programme from LegoChem Biosciences | The agreement provides Iksuda with exclusive world-wide rights (excluding Greater China and South Korea) to LCB’s Her2 ADC programme, LCB14. |
| SU013 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SU014 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SU015 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SU016 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SU017 | BigGo Finance | National Growth Fund backs LigaChem Bio; 15 out-licensing deals through 2024 | Since its first technology transfer ... in 2015, LigaChem Bio has signed a total of 15 out-licensing deals through 2024, with cumulative technology export value reaching 9.6 trillion won. |
| SU018 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SU019 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SU020 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SU021 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SU022 | National Cancer Institute | NCI Drug Dictionary - caxmotabart entudotin | |
| SU023 | LigaChem Biosciences | Iksuda initiates HER2-ADC (LCB14/IKS014) Phase 1 trial | Fosun Pharma holds the licence to the ADC in Greater China where it is designated FS-1502. |
| SU024 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 (ROR1 ADC) | In October 2020, CStone signed a licensing agreement with LigaChem Biosciences ... Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea. |
| SU025 | LigaChem Biosciences | LCB71 (ROR1 ADC), CStone Phase1a result in solid tumors and lymphomas | |
| SR001 | LigaChem Biosciences | Disclosure | Material Management Information related to Judgment of Investment(LNCB74(B7H4-ADC) 단독 개발 및 기술이전 권리 확보) |
| SR002 | LigaChem Biosciences | ESG Governance | As of the end of December 2023, the Company’s board of directors consists of three inside directors and two outside directors. |
| SR003 | LigaChem Biosciences | Leadership | Scientific Advisory Board ... ADC Toxicology·Safety ... ADC Manufacturing·CMC |
| SR004 | LigaChem Biosciences | History | |
| SR005 | LigaChem Biosciences | Careers - Process | Required Documents ... research statement ... Thesis abstract ... Recommendation letter from the academic advisor. |
| SR006 | LigaChem Biosciences | Financial Information - Balance Sheet | |
| SR007 | LigaChem Biosciences | Financial Information - Income Statement | |
| SR008 | LigaChem Biosciences | Financial Information - Cash Flow | |
| SR009 | BigGo Finance | National Growth Fund backs LigaChem Bio and outlines late-stage spending plan | |
| SR010 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SR011 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SR012 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SR013 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SR014 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SR015 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SR016 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SR017 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SR018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SR019 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SR020 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SR021 | Google Patents | US10383949B2 - Compounds comprising self-immolative group | Current Assignee ... Ligachem Biosciences Inc ... Legal status ... Active |
| SR022 | Google Patents | US11413353B2 - Conjugates comprising self-immolative groups and methods related thereto | Current Assignee ... Ligachem Biosciences Inc ... Active, expires 2039-11-11 |
| SR023 | Google Patents | US10407743B2 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs | Family has litigation |
| SR024 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | |
| SR025 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | |
| SR026 | NextCure | Pipeline | |
| SR027 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 | |
| SR028 | LigaChem Biosciences | Iksuda strategic investment and pipeline expansion | |
| SR029 | LigaChem Biosciences | SOT106 milestone and IND plan | |
| SR030 | LigaChem Biosciences | LCB71 / CS5001 Phase 1a result in solid tumors and lymphomas | |
| SR031 | LigaChem Biosciences | Iksuda initiates HER2-ADC (LCB14/IKS014) Phase 1 trial | |
| SR032 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | |
| SR033 | Google Patents | WO2017089890A1 - Conjugates comprising self-immolative groups and methods related thereto | |
| SR034 | Google Patents | US20200297865A1 - Conjugates comprising self-immolative groups and methods related thereto | |
| SR035 | Google Patents | US20170080103A1 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs | |
| SR036 | Korea Exchange | Disclosure search for Ligachem | |
| SR037 | ClinicalTrials.gov | Search results for Ligachem | |
| SV001 | LigaChem Biosciences | Disclosure | |
| SV002 | LigaChem Biosciences | Financial Information - Income Statement | |
| SV003 | LigaChem Biosciences | Financial Information - Cash Flow | |
| SV004 | Yahoo Finance | LigaChem Biosciences Inc. quote | Market Cap (intraday) 4.125T ... 1y Target Est 211,666.67 |
| SV005 | Yahoo Finance | LigaChem Biosciences analyst ratings, estimates & forecasts | Current Year (2026) Avg. Estimate 284B ... Next Year (2027) Avg. Estimate 286.48B |
| SV006 | BigGo Finance | National Growth Fund backs LigaChem Bio and outlines late-stage spending plan | |
| SV007 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SV008 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SV009 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SV010 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | |
| SV011 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | |
| SV012 | NextCure | Pipeline | |
| SV013 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 | |
| SV014 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SV015 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SV016 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SV017 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SV018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SV019 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SV020 | Google Patents | US11413353B2 - Conjugates comprising self-immolative groups and methods related thereto | |
| SV021 | Google Patents | US10383949B2 - Compounds comprising self-immolative group | |
| SV022 | Yahoo Finance | ADC Therapeutics SA quote | |
| SV023 | CompaniesMarketCap | ADC Therapeutics market capitalization | |
| SV024 | Yahoo Finance | Sutro Biopharma quote | |
| SV025 | CompaniesMarketCap | Sutro Biopharma market capitalization | |
| SV026 | Yahoo Finance | CStone Pharmaceuticals quote | |
| SV027 | Pfizer | Pfizer completes acquisition of Seagen | |
| SV028 | AbbVie | AbbVie completes acquisition of ImmunoGen | |
| SV029 | LigaChem Biosciences | Iksuda strategic investment and pipeline expansion | |
| SV030 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC |